Processes for Preparing a MDM2 Inhibitor

ABSTRACT

The present invention provides commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates thereof.

FIELD OF THE INVENTION

The present invention provides processes for preparing2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)aceticacid (“Compound A”) and intermediates thereof.

BACKGROUND OF THE INVENTION

p53 is a tumor suppressor and transcription factor that responds tocellular stress by activating the transcription of numerous genesinvolved in cell cycle arrest, apoptosis, senescence, and DNA repair.Unlike normal cells, which infrequently have a cause for p53 activation,tumor cells are under constant cellular stress from various insultsincluding hypoxia and pro-apoptotic oncogene activation. Thus, there isa strong selective advantage for inactivation of the p53 pathway intumors, and it has been proposed that eliminating p53 function may be aprerequisite for tumor survival. In support of this notion, three groupsof investigators have used mouse models to demonstrate that absence ofp53 function is a continuous requirement for the maintenance ofestablished tumors. When the investigators restored p53 function totumors with inactivated p53, the tumors regressed.

p53 is inactivated by mutation and/or loss in 50% of solid tumors and10% of liquid tumors. Other key members of the p53 pathway are alsogenetically or epigenetically altered in cancer. MDM2, an oncoprotein,inhibits p53 function, and it is activated by gene amplification atincidence rates that are reported to be as high as 10%. MDM2, in turn,is inhibited by another tumor suppressor, p14ARF. It has been suggestedthat alterations downstream of p53 may be responsible for at leastpartially inactivating the p53 pathway in p53^(WT) tumors. In support ofthis concept, some p53^(WT) tumors appear to exhibit reduced apoptoticcapacity, although their capacity to undergo cell cycle arrest remainsintact. One cancer treatment strategy involves the use of smallmolecules that bind MDM2 and neutralize its interaction with p53. MDM2inhibits p53 activity by three mechanisms: 1) acting as an E3 ubiquitinligase to promote p53 degradation; 2) binding to and blocking the p53transcriptional activation domain; and 3) exporting p53 from the nucleusto the cytoplasm. All three of these mechanisms would be blocked byneutralizing the MDM2-p53 interaction. In particular, this therapeuticstrategy could be applied to tumors that are p53^(W)T, and studies withsmall molecule MDM2 inhibitors have yielded promising reductions intumor growth both in vitro and in vivo. Further, in patients withp53-inactivated tumors, stabilization of wildtype p53 in normal tissuesby MDM2 inhibition might allow selective protection of normal tissuesfrom mitotic poisons.

The present invention relates to a compound capable of inhibiting theinteraction between p53 and MDM2 and activating p53 downstream effectorgenes. As such, the compound of the present invention would be useful inthe treatment of cancers, bacterial infections, viral infections, ulcersand inflammation. In particular, the compound of the present inventionis useful to treat solid tumors such as: breast, colon, lung andprostate tumors; and liquid tumors such as lymphomas and leukemias. Asused herein, MDM2 refers to a human MDM2 protein and p53 refers to ahuman p53 protein. Human MDM2 can also be referred to as HDM2 or hMDM2.

The compound,2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)aceticacid (also referred to herein as Compound A) is a MDM2 inhibitor and hasthe following chemical structure. Compound A is disclosed in publishedPCT Application No.

WO 2011/153509 (Example No. 362) and is being investigated in humanclinical trials for the treatment of various cancers. The presentinvention provides improved processes for preparing Compound A as wellas intermediate compounds thereof.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a process of preparingthe following compound (DHO)

the process comprising: reacting compound (ABA)

with methoxymethylene-N,N-dimethyliminium methyl sulfate. In anembodiment, this reaction is carried out in the presence of a base. In aparticular embodiment, the base is an alkali metal salt or an alkalineearth metal salt, such as, for example, KOAc, NaOAc, LiOAc, CaCO₃ andK₂CO₃. In an embodiment, the reaction is carried out in a solvent. In aparticular embodiment, the solvent is benzene, toluene, o-xylene,m-xylene, p-xylene, hexane, tetrahydrofuran, ethyl acetate, HMPA, HMPT,DMSO, ethylene glycol, DME, DMF, diethyl ether, acetonitrile, methanol,ethanol, acetone or mixtures thereof.

In one embodiment, the present invention provides a process of preparingcompound (SUL)

the process comprising: reacting compound

with an isopropylation agent such as, but not limited to,isopropylsulfinate zinc chloride. In an embodiment, the reaction iscarried out in presence of an alkaline earth metal salt. In a particularembodiment, the alkaline earth metal salt is a magnesium salt, such as,but not limited to, MgBr₂ or MgCl₂. In a particular embodiment, theisopropylation agent is generated in situ from isopropyl magnesiumchloride. In an embodiment, the reaction is carried out at a temperaturebetween 100° C. and 200° C., such as between 100° C. and 150° C., suchas at 120° C. or between 150° C. and 200° C., such as at 180° C.

In one embodiment, the present invention provides a crystalline form of(1R,2R,4S)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-4-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)-4-methylhept-6-en-1-ol(DHO) characterized by a reflection X-ray powder diffraction patterncomprising peaks at 7.3°±0.2° 2θ, 14.5°±0.2° 2θ, 15.8°±0.2° 2θ,15.9°±0.2° 2θ, and 23.1°±0.2° 2θ. In an embodiment, the reflection X-raypowder diffraction pattern of the DHO crystalline further comprisespeaks at 8.5°±0.2° 2θ, 10.0°±0.2° 2θ, 11.0°±0.2° 2θ, 13.4°±0.2° 2θ,18.8°±0.2° 2θ, and 22.0°±0.2° 2θ. In an embodiment, the reflection X-raypowder diffraction pattern of the DHO crystalline further comprises oneor more peaks at 6.3°±0.2° 2θ, 10.5°±0.2° 2θ, 11.5°±0.2° 2θ, 12.8°±0.2°2θ, 14.8°±0.2° 2θ, 15.2°±0.2° 2θ, 17.0°±0.2° 2θ, 17.5°±0.2° 2θ,17.80±0.2° 2θ, 18.4°±0.2° 2θ, 19.0°±0.2° 2θ, 19.7°±0.2° 2θ, 19.9°±0.2°2θ, 20.7°±0.2° 2θ, 21.2°±0.2° 2θ, 21.3°±0.2° 2θ, 22.4°±0.2° 2θ,23.6°±0.2° 2θ, 24.2°±0.2° 2θ, 24.9°±0.2° 2θ, 25.7°±0.2° 2θ, 26.3°±0.2°2θ, 27.0°±0.2° 2θ, 28.3°±0.2° 2θ, 28.7°±0.2° 2θ, 29.3°±0.2° 2θ,29.7°±0.2° 2θ, 30.8°±0.2° 2θ, 31.4°±0.2° 2θ, 31.8°±0.2° 2θ, 33.0°±0.2°2θ, 34.2°±0.2° 2θ, 35.8°±0.2° 2θ, 37.0°±0.2° 2θ, and 37.5°±0.2° 2θ. Inan embodiment, the crystalline form of DHO is a crystalline anhydrate.In an embodiment, the reflection x-ray powder diffraction of thecrystalline DHO is carried out using Cu-Kα radiation.

BRIEF DESCRIPTION OF THE DRAWINGS

The following figures represent specific embodiments of the invention asdescribed and are not intended to otherwise limit the invention.

FIG. 1 illustrates the conversion rate of(3S,5R,6R)-3-Allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one(DLAC) to(S)-2-((2R,3R)-2-(3-chlorophenyl)-3-(4-chlorophenyl)-3-hydroxypropyl)-N—((S)-1-hydroxy-3-methylbutan-2-yl)-2-methylpent-4-enamide(ABA) over time at 60° C.

FIG. 2 illustrates the conversion rate of DLAC to ABA over time at 115°C.

FIG. 3 illustrates the solubility of(1R,2R,4S)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-4-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)-4-methylhept-6-en-1-ol(DHO) during the crystallization process at 25° C.

FIG. 4 illustrates the yield of(3S,5R,6S)-3-allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methylpiperidin-2-one(SUL) over time using isopropylsulfinate magnesium chloride at 120° C.(14 mol % of water (vs(3S,5S,6R,8S)-8-allyl-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-isopropyl-8-methyl-2,3,5,6,7,8-hexahydrooxazolo[3,2-a]pyridin-4-iumnaphthalene-1-sulfonate, hemi toluene solvate (OXOS)) in the reactionmixture).

FIG. 5 illustrates the yield of SUL over time using isopropylsulfinatemagnesium chloride at 180° C. (11 mol % of water (vs OXOS) in thereaction mixture).

FIG. 6 illustrates ¹H NMR analyses of different isopropyl sulfinatespecies in THF-ds.

FIG. 7 illustrates the yield of SUL over time using Mg sulfinate-ZnCl₂at 120° C. (17 mol % of water (vs OXOS) in the reaction mixture).

FIG. 8 illustrates the yield of SUL over time using Mg sulfinate-ZnCl₂at 180° C. (17 mol % of water (vs OXOS) in the reaction mixture).

FIG. 9 illustrates the(3R,5R,6S)-3-((1,2,4-trioxolan-3-yl)methyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methylpiperidin-2-one(OZO) LC area % relative to water wt % in the reaction mixture at 20° C.

FIG. 10 illustrates a schematic of an apparatus for continuous modeozonolysis and Pinnick oxidation.

FIG. 11 illustrates a picture of the continuous ozonolysis processingapparatus.

FIG. 12 illustrates a schematic of an apparatus for semi-batch modeozonolysis and Pinnick oxidation.

FIG. 13 illustrates the consumption rate of SUL for semi-batch modeozonolysis.

FIG. 14 illustrates sparger evolution for ozonolysis manufacturingdevelopment.

FIG. 15 illustrates the solubility of 232-DAB during the crystallizationprocess.

FIG. 16 illustrates the solubility of Compound A during thecrystallization process.

FIG. 17 illustrates a powder X-ray diffraction (PXRD) pattern ofcrystalline DHO measured in reflection mode.

FIG. 18 illustrates a powder X-ray diffraction (PXRD) pattern ofcrystalline DHO measured in reflection mode with sticks, indicating thepeak positions.

FIG. 19 illustrates a thermogram from differential scanning calorimetry(DSC) analysis of crystalline DHO.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides processes for preparing2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)aceticacid (“Compound A”) as well as intermediates thereof and processes forpreparing these intermediates.

In one aspect, the present invention provides a process for themanufacture of Compound A in high purity.

In another aspect, the present invention employs a bench-stableVilsmeier reagent, methoxymethylene-N,N-dimethyliminium methyl sulfate(Corbett, M. T.; Caille, S., Synlett 2007, 28, 2845), to achieve theselective in situ activation of a primary alcohol intermediate in thepreparation of Compound A.

In another aspect, the present disclosure employs a bench-stablecrystalline isopropylation agent, isopropyl calcium sulfinate, toachieve the high-yielding preparation of a sulfone intermediate in thepreparation of Compound A.

In another aspect, the present disclosure employs a safe ozonolysisreaction conducted in an aqueous solvent mixture in either a batch orcontinuous manufacturing mode in the process of preparing Compound A.

In another aspect, the present invention provides a crystalline form of(1R,2R,4S)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-4-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)-4-methylhept-6-en-1-ol(DHO) characterized by a reflection X-ray powder diffraction patterncomprising peaks at 7.3°±0.2° 2θ, 14.5°±0.2° 2θ, 15.8°±0.2° 2θ,15.9°±0.2° 2θ, and 23.1°±0.2° 2θ. In an embodiment, the reflection X-raypowder diffraction pattern of the DHO crystalline further comprisespeaks at 8.5°±0.2° 2θ, 10.0°±0.2° 2θ, 11.0°±0.2° 2θ, 13.4°±0.2° 2θ,18.8°±0.2° 2θ, and 22.0°±0.2° 2θ. In an embodiment, the reflection X-raypowder diffraction pattern of the DHO crystalline further comprises oneor more peaks at 6.3°±0.2° 2θ, 10.5°±0.2° 2θ, 11.5°±0.2° 2θ, 12.8°±0.2°2θ, 14.8°±0.2° 2θ, 15.2°±0.2° 2θ, 17.0°±0.2° 2θ, 17.5°±0.2° 2θ,17.8°±0.2° 2θ, 18.4°±0.2° 2θ, 19.0°±0.2° 2θ, 19.7°±0.2° 2θ, 19.9°±0.2°2θ, 20.7°±0.2° 2θ, 21.20±0.2° 2θ, 21.3°±0.2° 2θ, 22.4°±0.2° 2θ,23.6°±0.2°±2θ, 24.2°±0.2°±2θ, 24.9°±0.2° 2θ, 25.7°±0.2° 2θ, 26.3°±0.2°2θ, 27.0°±0.2° 2θ, 28.3°±0.2°±2θ, 28.7°±0.2°±2θ, 29.3° 0.2° 2θ,29.7°±0.2° 2θ, 30.8°±0.2° 2θ, 31.4°±0.2°±2θ, 31.8°±0.2°±2θ, 33.0°±0.2°2θ, 34.2°±0.2° 2θ, 35.8°±0.2° 2θ, 37.0°±0.2°±2θ, and 37.5°±0.2°±2θ. Inan embodiment, the crystalline form of DHO is a crystalline anhydrate.In an embodiment, the reflection x-ray powder diffraction of thecrystalline DHO is carried out using Cu-Kα radiation.

In another aspect, the present disclosure provides control of the purityof Compound A by crystallization of a 1,4-diazabicyclo[2.2.2]octane(DABCO) salt thereof, which can be effectively purified.

In one embodiment, the present invention provides a process suitable forscale-up of preparing Compound A (99.9 LC area %) in 49.8% overall yieldfrom the starting material DLAC.

The term “comprising” is intended to be open ended, including theindicated component but not excluding other elements.

The term “therapeutically effective amount” refers to an amount of acompound or combination of therapeutically active compounds thatameliorates, attenuates or eliminates one or more symptoms of aparticular disease or condition, or prevents or delays the onset of oneof more symptoms of a particular disease or condition.

The terms “patient” and “subject” may be used interchangeably and referto animals, such as dogs, cats, cows, horses, sheep and humans.Particular patients are mammals. The term patient includes males andfemales.

The term “pharmaceutically acceptable” means that the referencedsubstance, such as a compound of the present invention, or a salt of thecompound, or a formulation containing the compound, or a particularexcipient, is suitable for administration to a patient.

The terms “treating”, “treat” or “treatment” and the like includepreventative (e.g., prophylactic) and palliative treatments.

The term “excipient” refers to any pharmaceutically acceptable additive,carrier, diluent, adjuvant, or other ingredient, other than the activepharmaceutical ingredient (API), which is typically included forformulation and/or administration to a patient.

The compound(s) of the present invention can be administered to apatient in a therapeutically effective amount. The compound(s) can beadministered alone or as part of a pharmaceutically acceptablecomposition or formulation. In addition, the compound(s) or compositionscan be administered all at once, as for example, by a bolus injection,multiple times, such as by a series of tablets, or deliveredsubstantially uniformly over a period of time, as for example, usingtransdermal delivery. It is also noted that the dose of the compound(s)can be varied over time.

The compound(s) of the present invention, or the pharmaceuticallyacceptable salts thereof, may also be administered in combination withone or more additional pharmaceutically active compounds/agents. It isnoted that the additional pharmaceutically active compounds/agents maybe a traditional small organic chemical molecule or can be amacromolecule such as proteins, antibodies, peptibodies, DNA, RNA orfragments of such macromolecules.

When a patient is to receive or is receiving multiple pharmaceuticallyactive compounds, the compounds can be administered simultaneously, orsequentially. For example, in the case of tablets, the active compoundsmay be found in one tablet or in separate tablets, which can beadministered at once or sequentially in any order. In addition, itshould be recognized that the compositions may be different forms. Forexample, one or more compounds may be delivered via a tablet, whileanother may be administered via injection or orally as a syrup. Allcombinations, delivery methods and administration sequences arecontemplated.

The term “cancer” refers to a physiological condition in mammals that ischaracterized by unregulated cell growth. General classes of cancersinclude carcinomas, lymphomas, sarcomas, and blastomas.

The compound(s) of the present invention can be used to treat cancer.The methods of treating a cancer comprise administering to a patient inneed thereof a therapeutically effective amount of the compound, or apharmaceutically acceptable salt thereof.

The compound(s) of the present invention can be used to treat tumors.The methods of treating a tumor comprise administering to a patient inneed thereof a therapeutically effective amount of the compound, or apharmaceutically acceptable salt thereof.

The invention also relates to the use of the compound(s) of the presentinvention in the manufacture of a medicament for the treatment of acondition such as a cancer.

Cancers which may be treated with the compound(s) of the presentinvention include, without limitation, carcinomas such as cancer of thebladder, breast, colon, rectum, kidney, liver, lung (small cell lungcancer, and non-small-cell lung cancer), esophagus, gall-bladder, ovary,pancreas, stomach, cervix, thyroid, prostate, and skin (includingsquamous cell carcinoma); hematopoietic tumors of lymphoid lineage(including leukemia, acute lymphocytic leukemia, chronic myelogenousleukemia, acute lymphoblastic leukemia, B-cell lymphoma,T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy celllymphoma and Burkett's lymphoma); hematopoietic tumors of myeloidlineage (including acute and chronic myelogenous leukemias,myelodysplastic syndrome and promyelocytic leukemia); tumors ofmesenchymal origin (including fibrosarcoma and rhabdomyosarcoma, andother sarcomas, e.g., soft tissue and bone); tumors of the central andperipheral nervous system (including astrocytoma, neuroblastoma, gliomaand schwannomas); and other tumors (including melanoma, seminoma,teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma,thyroid follicular cancer and Kaposi's sarcoma). Other cancers that canbe treated with the compound(s) of the present invention includeendometrial cancer, head and neck cancer, glioblastoma, malignantascites, and hematopoietic cancers.

Particular cancers that can be treated by the compound(s) of the presentinvention include soft tissue sarcomas, bone cancers such asosteosarcoma, breast tumors, bladder cancer, Li-Fraumeni syndrome, braintumors, rhabdomyosarcoma, adrenocortical carcinoma, colorectal cancer,non-small cell lung cancer, and acute myelogenous leukemia (AML).

In a particular embodiment of the invention that relates to thetreatment of cancers, the cancer is identified as p53wildtype(p53^(WT)). In another particular embodiment, the cancer is identifiedas p53^(WT) and a CDKN2A mutant. In another aspect, the presentinvention provides a diagnostic for determining which patients should beadministered a compound of the present invention. For example, a sampleof a patient's cancer cells may be taken and analyzed to determine thestatus of the cancer cells with respect to p53 and/or CDKN2A. In oneaspect, a patient having a cancer that is p53^(WT) will be selected fortreatment over patients having a cancer that is mutated with respect top53. In another aspect, a patient having a cancer that is both p53^(WT)and has a mutant CDNK2A protein is selected over a patient that does nothave these characteristics. The taking of a cancer cells for analyses iswell known to those skilled in the art. The term “p53^(WT)” refers to aprotein encoded by genomic DNA sequence no. NC_000017 version 9 (7512445. . . 7531642)(GenBank); a protein encoded by cDNA sequence no.NM_000546 (GenBank); or a protein having the GenBank sequence no.NP_000537.3. The term “CDNK2A mutant” means a CDNK2A protein that is notwildtype. The term “CDKN2A wildtype” refers to a protein encoded bygenomic DNA sequence no. 9:21957751-21984490 (Ensembl ID); a proteinencoded by cDNA sequence no. NM_000077 (GenBank) or NM_058195 9GenBank)or; or a protein having the GenBank sequence no. NP_000068 or NP_478102.

In another aspect, the present invention relates to the use of thecompound(s) of the present invention in combination with one or morepharmaceutical agents that is an inhibitor of a protein in thephosphatidylinositol 3-kinase (PI3K) pathway. Combinations of thecompound(s) of the present invention with inhibitors of proteins in thePI3K pathway have shown synergy in cancer cell growth assays, includingenhanced apoptosis and cell killing. Examples of proteins in the PI3Kpathway include PI3K, mTOR and PKB (also known as Akt). The PI3K proteinexists in several isoforms including α, β, δ, or γ. It is contemplatedthat a PI3K inhibitor that can be used in combination with a compound ofthe present invention can be selective for one or more isoform. Byselective it is meant that the compound(s) inhibit one or more isoformsmore than other isoforms. Selectivity is a concept well known to thosein the art and can be measured with well-known activity in in vitro orcell-based assays. Preferred selectivity includes greater than 2-fold,preferably 10-fold, or more preferably 100-fold greater selectivity forone or more isoforms over the other isoforms. In one aspect, the PI3Kinhibitors that can be used in combination with compound(s) of thepresent invention is a PI3K a selective inhibitor. In another aspect thecompound is a PI3K 6 selective inhibitor.

Examples of PI3K inhibitors that can be used in combination with thecompound(s) of the present invention include those disclosed in, forexample, WO 2010/151791; WO 2010/151737; WO 2010/151735; WO 2010/151740;WO 2008/118455; WO 2008/118454; WO 2008/118468; US 20100331293; US20100331306; US 20090023761; US 20090030002; US 20090137581; US20090054405; US 20090163489; US 20100273764; US 20110092504; or WO2010/108074.

Compounds that inhibit both PI3K and mTOR (dual inhibitors) are known.In still another aspect, the present invention provides the use of dualPI3K and mTOR inhibitors for use in combination with the compound(s) ofthe present invention.

mTOR is a protein in the PI3K pathway. It is another aspect of thepresent invention to use an mTOR inhibitor in combination with thecompound(s) of the present invention. Suitable mTOR inhibitors that canbe used in combination with the compound(s) of the present inventioninclude those disclosed in, for example, WO 2010/132598 and WO2010/096314.

PKB (Akt) is also a protein in the PI3K pathway. It is another aspect ofthe present invention to use an mTOR inhibitor in combination with thecompound(s) of the present invention. PKB inhibitors that can be used incombination with the compound(s) of the present invention include thosedisclosed in, for example, U.S. Pat. Nos. 7,354,944; 7,700,636;7,919,514; 7,514,566; US 20090270445 A1; U.S. Pat. Nos. 7,919,504;7,897,619; and WO 2010/083246.

The combinations of the present invention may also be used inconjunction with radiation therapy, hormone therapy, surgery andimmunotherapy, which therapies are well known to those skilled in theart.

Since one aspect of the present invention contemplates the treatment ofthe disease/conditions with a combination of pharmaceutically activecompounds that may be administered separately, the invention furtherrelates to combining separate pharmaceutical compositions in kit form.The kit comprises two separate pharmaceutical compositions: a compoundof the present invention, and a second pharmaceutical compound. The kitcomprises a container for containing the separate compositions such as adivided bottle or a divided foil packet. Additional examples ofcontainers include syringes, boxes and bags. Typically, the kitcomprises directions for the use of the separate components. The kitform is particularly advantageous when the separate components arepreferably administered in different dosage forms (e.g., oral andparenteral), are administered at different dosage intervals, or whentitration of the individual components of the combination is desired bythe prescribing physician or veterinarian.

An example of such a kit is a so-called blister pack. Blister packs arewell known in the packaging industry and are being widely used for thepackaging of pharmaceutical unit dosage forms (tablets, capsules, andthe like). Blister packs generally consist of a sheet of relativelystiff material covered with a foil of a preferably transparent plasticmaterial. During the packaging process recesses are formed in theplastic foil. The recesses have the size and shape of the tablets orcapsules to be packed. Next, the tablets or capsules are placed in therecesses and the sheet of relatively stiff material is sealed againstthe plastic foil at the face of the foil which is opposite from thedirection in which the recesses were formed. As a result, the tablets orcapsules are sealed in the recesses between the plastic foil and thesheet. Preferably the strength of the sheet is such that the tablets orcapsules can be removed from the blister pack by manually applyingpressure on the recesses whereby an opening is formed in the sheet atthe place of the recess. The tablet or capsule can then be removed viasaid opening.

It may be desirable to provide a memory aid on the kit, e.g., in theform of numbers next to the tablets or capsules whereby the numberscorrespond with the days of the regimen which the tablets or capsules sospecified should be ingested. Another example of such a memory aid is acalendar printed on the card, e.g., as follows “First Week, Monday,Tuesday, . . . etc. . . . . Second Week, Monday, Tuesday, . . . ” etc.Other variations of memory aids will be readily apparent. A “daily dose”can be a single tablet or capsule or several pills or capsules to betaken on a given day. Also, a daily dose of a compound of the presentinvention can consist of one tablet or capsule, while a daily dose ofthe second compound can consist of several tablets or capsules and viceversa. The memory aid should reflect this and aid in correctadministration of the active agents.

In another specific embodiment of the invention, a dispenser designed todispense the daily doses one at a time in the order of their intendeduse is provided. Preferably, the dispenser is equipped with amemory-aid, so as to further facilitate compliance with the regimen. Anexample of such a memory-aid is a mechanical counter which indicates thenumber of daily doses that has been dispensed. Another example of such amemory-aid is a battery-powered micro-chip memory coupled with a liquidcrystal readout, or audible reminder signal which, for example, readsout the date that the last daily dose has been taken and/or reminds onewhen the next dose is to be taken.

The compound(s) of the present invention and other pharmaceuticallyactive compounds, if desired, can be administered to a patient eitherorally, rectally, parenterally (for example, intravenously,intramuscularly, or subcutaneously) intracisternally, intravaginally,intraperitoneally, intravesically, locally (for example, powders,ointments or drops), or as a buccal or nasal spray. All methods that areused by those skilled in the art to administer a pharmaceutically activeagent are contemplated.

Compositions suitable for parenteral injection may comprisephysiologically acceptable sterile aqueous or nonaqueous solutions,dispersions, suspensions, or emulsions, and sterile powders forreconstitution into sterile injectable solutions or dispersions.Examples of suitable aqueous and nonaqueous carriers, diluents,solvents, or vehicles include water, ethanol, polyols (propylene glycol,polyethylene glycol, glycerol, and the like), suitable mixtures thereof,vegetable oils (such as olive oil) and injectable organic esters such asethyl oleate. Proper fluidity can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preserving,wetting, emulsifying, and dispersing agents. Microorganism contaminationcan be prevented by adding various antibacterial and antifungal agents,for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.It may also be desirable to include isotonic agents, for example,sugars, sodium chloride, and the like. Prolonged absorption ofinjectable pharmaceutical compositions can be brought about by the useof agents delaying absorption, for example, aluminum monostearate andgelatin.

Solid dosage forms for oral administration include capsules, tablets,powders, and granules. In such solid dosage forms, the active compoundis admixed with at least one inert customary excipient (or carrier) suchas sodium citrate or dicalcium phosphate or (a) fillers or extenders, asfor example, starches, lactose, sucrose, mannitol, and silicic acid; (b)binders, as for example, carboxymethylcellulose, alginates, gelatin,polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, as forexample, glycerol; (d) disintegrating agents, as for example, agar-agar,calcium carbonate, potato or tapioca starch, alginic acid, certaincomplex silicates, and sodium carbonate; (a) solution retarders, as forexample, paraffin; (f) absorption accelerators, as for example,quaternary ammonium compounds; (g) wetting agents, as for example, cetylalcohol and glycerol monostearate; (h) adsorbents, as for example,kaolin and bentonite; and (i) lubricants, as for example, talc, calciumstearate, magnesium stearate, solid polyethylene glycols, sodium laurylsulfate, or mixtures thereof. In the case of capsules, and tablets, thedosage forms may also comprise buffering agents. Solid compositions of asimilar type may also be used as fillers in soft and hard filled gelatincapsules using such excipients as lactose or milk sugar, as well as highmolecular weight polyethylene glycols, and the like.

Solid dosage forms such as tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells, such as entericcoatings and others well known in the art. They may also containopacifying agents, and can also be of such composition that they releasethe active compound or compounds in a certain part of the intestinaltract in a delayed manner. Examples of embedding compositions that canbe used are polymeric substances and waxes. The active compound can alsobe in micro-encapsulated form, if appropriate, with one or more of theabove-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups, and elixirs. Inaddition to the active compounds, the liquid dosage form may containinert diluents commonly used in the art, such as water or othersolvents, solubilizing agents and emulsifiers, as for example, ethylalcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,dimethylformamide, oils, in particular, cottonseed oil, groundnut oil,corn germ oil, olive oil, castor oil, and sesame seed oil, glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, or mixtures of these substances, and the like.

Besides such inert diluents, the composition can also include adjuvants,such as wetting agents, emulsifying and suspending agents, sweetening,flavoring, and perfuming agents. Suspensions, in addition to the activecompound(s), may contain suspending agents, as for example, ethoxylatedisostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters,microcrystalline cellulose, aluminum metahydroxide, bentonite,agar-agar, and tragacanth, or mixtures of these substances, and thelike.

Compositions for rectal administration are preferable suppositories,which can be prepared by mixing the compounds of the present inventionwith suitable non-irritating excipients or carriers such as cocoabutter, polyethylene glycol or a suppository wax, which are solid atordinary room temperature, but liquid at body temperature, andtherefore, melt in the rectum or vaginal cavity and release the activecomponent.

Dosage forms for topical administration of the compound(s) of thepresent invention include ointments, powders, sprays and inhalants. Theactive compound or compounds are admixed under sterile condition with aphysiologically acceptable carrier, and any preservatives, buffers, orpropellants that may be required. Ophthalmic formulations, eyeointments, powders, and solutions are also contemplated as being withinthe scope of this invention.

The compound(s) of the present invention can be administered to apatient at dosage levels in the range of about 0.1 to about 3,000 mg perday. For a normal adult human having a body weight of about 70 kg, adosage in the range of about 0.01 to about 100 mg per kilogram bodyweight is typically sufficient. The specific dosage and dosage rangethat can be used depends on a number of factors, including therequirements of the patient, the severity of the condition or diseasebeing treated, and the pharmacological activity of the compound beingadministered. The determination of dosage ranges and optimal dosages fora particular patient is within the ordinary skill in the art.

The compound(s) of the present invention can be administered aspharmaceutically acceptable salts, esters, amides or prodrugs. The term“salts” refers to inorganic and organic salts of compounds of thepresent invention. The salts can be prepared in situ during the finalisolation and purification of a compound, or by separately reacting apurified compound in its free base or acid form with a suitable organicor inorganic base or acid and isolating the salt thus formed.

Examples of pharmaceutically acceptable esters of the compound(s) of thepresent invention include C₁-C₈ alkyl esters. Acceptable esters alsoinclude C₅-C₇ cycloalkyl esters, as well as arylalkyl esters such asbenzyl. C₁-C₄ alkyl esters are commonly used. Esters of the compound(s)of the present invention may be prepared according to methods that arewell known in the art.

Examples of pharmaceutically acceptable amides of the compound(s) of thepresent invention include amides derived from ammonia, primary C₁-C₈alkyl amines, and secondary C₁-C₈ dialkyl amines. In the case ofsecondary amines, the amine may also be in the form of a 5- or6-membered heterocycloalkyl group containing at least one nitrogen atom.Amides derived from ammonia, C₁-C₃ primary alkyl amines and C₁-C₂dialkyl secondary amines are commonly used. Amides of the compound(s) ofthe present invention may be prepared according to methods well known tothose skilled in the art.

The term “prodrug” refers to compounds that are transformed in vivo toyield a compound of the present invention. The transformation may occurby various mechanisms, such as through hydrolysis in blood. A discussionof the use of prodrugs is provided by T. Higuchi and W. Stella,“Prodrugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. SymposiumSeries, and in Bioreversible Carriers in Drug Design, ed. Edward B.Roche, American Pharmaceutical Association and Pergamon Press, 1987.

To illustrate, because the compound(s) of the invention contain acarboxylic acid functional group, a prodrug can comprise an ester formedby the replacement of the hydrogen atom of the carboxylic acid groupwith a group such as C₁-C₈ alkyl, (C₂-C₁₂)alkanoyloxymethyl,1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms,1-methyl-1-(alkanoyloxy)ethyl having from 5 to 10 carbon atoms,alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms,1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms,1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms,N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms,1-(N-(alkoxycarbonyl)aminomethyl having from 4 to 10 carbon atoms,3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl,di-N,N—(C₁-C₂)alkylamino(C₂-C₃)alkyl (such as β-dimethylaminoethyl),carbamoyl-(C₁-C₂)alkyl, N,N-di(C₁-C₂)alkylcarbamoyl-(C₁-C₂)alkyl andpiperidino-, pyrrolidino- or morpholino(C₂₋₃)alkyl.

The compound(s) of the present invention may contain asymmetric orchiral centers, and therefore, exist in different stereoisomeric forms.It is contemplated that all stereoisomeric forms of the compound(s) aswell as mixtures thereof, including racemic mixtures, form part of thepresent invention. In addition, the present invention contemplates allgeometric and positional isomers. For example, if the compound containsa double bond, both the cis and trans forms (designated as Z and E,respectively), as well as mixtures thereof, are contemplated.

Mixtures of stereoisomers, such as diastereomeric mixtures, can beseparated into their individual stereochemical components on the basisof their physical chemical differences by known methods such aschromatography and/or fractional crystallization. Enantiomers can alsobe separated by converting the enantiomeric mixture into adiastereomeric mixture by reaction with an appropriate optically activecompound (e.g., an alcohol), separating the resulting diastereomers andthen converting (e.g., hydrolyzing) the individual diastereomers to thecorresponding pure enantiomers.

The compound(s) of the present invention may exist in unsolvated as wellas solvated forms with pharmaceutically acceptable solvents such aswater (hydrate), ethanol, and the like. The present inventioncontemplates and encompasses both the solvated and unsolvated forms asset forth herein.

It is also possible that the compound(s) of the present invention mayexist in different tautomeric forms. All tautomers of the compound(s) ofthe present invention are contemplated. For example, all of thetautomeric forms of the tetrazole moiety are included in this invention.Also, for example, all keto-enol or imine-enamine forms of thecompound(s) are included in this invention.

Those skilled in the art will recognize that the compound names andstructures contained herein may be based on a particular tautomer of acompound. While the name or structure for only a particular tautomer maybe used, it is intended that all tautomers are encompassed by thepresent invention, unless stated otherwise.

It is also intended that the present invention encompasses compoundsthat are synthesized in vitro using laboratory techniques, such as thosewell known to synthetic chemists; or synthesized using in vivotechniques, such as through metabolism, fermentation, digestion, and thelike. It is also contemplated that the compound(s) of the presentinvention may be synthesized using a combination of in vitro and in vivotechniques.

The present invention also includes isotopically-labelled compounds,which are identical to those recited herein, but for the fact that oneor more atoms are replaced by an atom having an atomic mass or massnumber different from the atomic mass or mass number usually found innature. Examples of isotopes that can be incorporated into compound(s)of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen,phosphorous, fluorine and chlorine, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁶O,¹⁷O, ¹⁸O, ³¹P, ³²P ³⁵S, ¹⁸F, and ³⁶Cl. In one aspect, the presentinvention relates to compounds wherein one or more hydrogen atom isreplaced with deuterium (²H) atoms.

The compound(s) of the present invention that contain the aforementionedisotopes and/or other isotopes of other atoms are within the scope ofthis invention. Certain isotopically-labelled compounds of the presentinvention, for example those into which radioactive isotopes such as ³Hand ¹⁴C are incorporated, are useful in drug and/or substrate tissuedistribution assays. Tritiated, i.e., ³H, and carbon-14, i.e., ¹⁴C,isotopes are particularly preferred for their ease of preparation anddetection. Further, substitution with heavier isotopes such asdeuterium, i.e., ²H, can afford certain therapeutic advantages resultingfrom greater metabolic stability, for example increased in vivohalf-life or reduced dosage requirements and, hence, may be preferred insome circumstances. Isotopically labeled compounds of this invention cangenerally be prepared by substituting a readily available isotopicallylabeled reagent for a non-isotopically labeled reagent.

The compound(s) of the present invention may exist in various solidstates including crystalline states and as an amorphous state. Thedifferent crystalline states (also called polymorphs) and the amorphousstate of the present compound(s) are contemplated as part of thisinvention as set forth herein.

In synthesizing the compound(s) of the present invention, it may bedesirable to employ certain leaving groups. The term “leaving groups”(“LG”) generally refers to groups that are displaceable by anucleophile. Such leaving groups are known in the art. Examples ofleaving groups include, but are not limited to, halides (e.g., I, Br, F,Cl), sulfonates (e.g., mesylate, tosylate), sulfides (e.g., SCH₃),N-hydroxsuccinimide, N-hydroxybenzotriazole, and the like. Examples ofnucleophiles include, but are not limited to, amines, thiols, alcohols,Grignard reagents, anionic species (e.g., alkoxides, amides, carbanions)and the like.

All patents, published patent applications and other publicationsrecited herein are hereby incorporated by reference.

The specific experimental examples presented in this applicationillustrate specific embodiments of the present invention. These examplesare meant to be representative and are not intended to limit the scopeof the claims in any manner.

¹H-NMR spectra were typically acquired on a Bruker Avance III 500spectrometer system (Bruker, Billerica, MA) operating at a ¹H frequencyof 500.13 MHz, equipped with a Bruker 5 mm PABBI probe with a z-axisgradient; or on a Bruker Avance II or Avance III 400 spectrometeroperating at a ¹H frequency of 400.23 MHz, equipped with a Bruker 5 mmPABBO probe with a z-axis gradient. Samples were typically dissolved in500 μL of either DMSO-d₆ or CD₃OD for NMR analysis. ¹H chemical shiftsare referenced to the residual solvent signals from DMSO-d₆ at δ 2.50and CD₃OD at δ 3.30.

Significant peaks are tabulated and typically include the number ofprotons, multiplicity (s, singlet; d, doublet; dd, doublet of doublets;t, triplet; q, quartet; m, multiplet; br s, broad singlet) and couplingconstant(s) in Hertz (Hz). Electron Ionization (EI) mass spectra weretypically recorded on an Agilent Technologies 6140 Quadrupole LC/MS massspectrometer (Agilent Technologies, Englewood, CO). Mass spectrometryresults are reported as the ratio of mass over charge, sometimesfollowed by the relative abundance of each ion (in parentheses).Starting materials in the Examples below are typically either availablefrom commercial sources such as Sigma-Aldrich, St. Louis, MO, or viapublished literature procedures.

X-Ray powder diffraction data (XRPD) were obtained using a Bruker D8Discover X-ray diffraction system (Bruker, Billerica, MA) equipped witha Braun detector and a Cu-Kα radiation source operating inBragg-Brentano reflection geometry. 2θ values are generally accurate towithin an error of ±0.2°. The samples were generally prepared withoutany special treatment other than the application of slight pressure toget a flat surface. Samples were measured uncovered unless otherwisenoted. Operating conditions included a tube voltage of 40 kV and currentof 40 mA. A variable divergence slit was used with a 3° window. The stepsize was 0.019 020 with a step time of 35.2 seconds, and the scanningrange is: 3-40.4°.

Differential scanning calorimetry (DSC) was carried out with a PerkinElmer DSC-7 or with a TA Instruments Q2000 instrument. Samples wereprepared in a closed gold sample pan at temperature ramp rates of 5°C./minute from 20° C. up to approximately 350° C. The DSC thermogram ofcrystalline DHO is shown in FIG. 19 with a melting point at 73.86°.

EXAMPLES Example 1: Method for Preparing Selected Intermediates

Step A. 2-(3-Chlorophenyl)-1-(4-chlorophenyl)ethanone

Sodium bis(trimethylsilyl)amide (1 M in tetrahydrofuran, 117 mL) wasslowly added to a −78° C. solution of 2-(3-chlorophenyl) acetic acid (10g, 58.6 mmol) in tetrahydrofuran (58 mL) over 1 hour. After stirring at−78° C. for 40 minutes, a solution of methyl 4-chlorobenzoate (10 g,58.6 mmol) in tetrahydrofuran (35 mL) was added over a period of 10minutes. The reaction was stirred at −78° C. for 3 hours and thenallowed to warm to 25° C. After two hours at 25° C., the reaction wasquenched with saturated aqueous ammonium chloride solution, and most ofthe tetrahydrofuran was removed under reduced pressure. The residue wasextracted with ethyl acetate (2×100 mL). The combined organic layerswere washed with a saturated sodium chloride solution, dried over sodiumsulfate, filtered and the filtrate was concentrated. The product wasrecrystallized from ether/pentane to provide the2-(3-chlorophenyl)-1-(4-chlorophenyl)ethanone as a white solid.

Alternative Procedure for Preparing2-(3-Chlorophenyl)-1-(4-chlorophenyl)ethanone

To a mixture of chlorobenzene (170 L, 1684 mol), 3-chlorophenylaceticacid (50 Kg, 293 mol), and dimethylformamide (0.7 L, 9 mol) at 0° C. wasadded thionyl chloride (39.1 Kg, 329 mol) over the course of 30 min. Themixture was warmed to 15° C. and agitated for 6 h. The mixture wascooled to 0° C. and aluminum chloride (43 Kg, 322 mol) was added overthe course of 1.5 h. The mixture was warmed to 20° C. and agitated for15 h. Water (200 L) and ethanol (200 L) were added to the mixture andthe biphasic mixture was agitated for 2 h. The phases were separated andthe organic phase was washed twice with aqueousethylenediaminetetraacetic acid tetrasodium salt (3 wt %, 200 L), andonce with water (200 L). Heptane (1600 L) was added to the organic phaseover the course of 15 minutes. The suspension was agitated for 30minutes, cooled to −5° C., and filtered. The filtered material was driedat 40° C. for 20 h. 2-(3-Chlorophenyl)-1-(4-chlorophenyl)ethanone wasisolated in 83.6% yield (67.4 Kg). ¹H NMR (500 MHz, DMSO-d₆, δ ppm):8.05 (m, 2H), 7.62 (m, 2H), 7.33 (m, 3H), 7.21 (br d, J=7.3 Hz, 1H),4.45 (s, 2H). MS (ESI)=265.1 [M+H]⁺.

Step B: Methyl4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate

Methyl methacrylate (12.65 mL, 119 mmol) was added to a solution of2-(3-chlorophenyl)-1-(4-chlorophenyl)ethanone (30 g, 113 mmol) (fromStep A) in tetrahydrofuran (283 mL). Potassium tert-butoxide (1.27 g,11.3 mmol) was then added and the reaction was stirred at roomtemperature for 2 days. The solvent was then removed under vacuum andreplaced with 300 mL of ethyl acetate. The organic phase was washed withbrine (50 mL), water (3×50 mL), and brine (50 mL). The organic phase wasdried over magnesium sulfate, filtered and concentrated under vacuum toafford methyl4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate as anapproximately 1:1 mixture of diastereomers. ¹H NMR (400 MHz, CDCl₃, δppm): 7.87 (m, 2H), 7.38 (m, 2H), 7.27-7.14 (series of m, 4H), 4.61 (m,1H), 3.69 (s, 1.5H), 3.60 (s, 1.5 H), 2.45 (m, 1H), 2.34 (m, 1H), 2.10(ddd, J=13.9, 9.4, 5.5 Hz, 0.5H), 1.96 (ddd, J=13.7, 9.0, 4.3 Hz, 0.5H),1.22 (d, J=7.0 Hz, 1.5H), 1.16 (d, J=7.0, 1.5 H). MS (ESI)=387.0[M+23]+.

Step C:(3S,5R,6R)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-oneand(3R,5R,6R)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one

Methyl 4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate(40 g, 104.0 mmol) (from Step B) was dissolved in 200 mL of anhydroustoluene and concentrated under vacuum. The residue was placed under highvacuum for 2 hours before use. The compound was split into 2×20 gbatches and processed as follows: methyl4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate (20 g,52.0 mmol) in anhydrous 2-propanol (104 mL) was treated with potassiumtert-butoxide (2.33 g, 20.8 mmol) in a 250 mL glass hydrogenationvessel. RuCl₂(S-xylbinap)(S-DAIPEN) (0.191 g, 0.156 mmol, StremChemicals, Inc., Newburyport, MA) in 3.8 mL of toluene was added. After1.5 hours, the vessel was pressurized to 50 psi (344.7 kPa) and purgedwith hydrogen five times and allowed to stir at room temperature. Thereaction was recharged with additional hydrogen as needed. After 3 days,the reactions were combined and partitioned between 50% saturatedammonium chloride solution and ethyl acetate. The aqueous layer wasextracted with ethyl acetate. The combined organic phases were washedwith brine, dried over magnesium sulfate, filtered, and concentrated.

The crude product (predominantly, (4R,5R)-isopropyl4-(3-chlorophenyl)-5-(4-chlorophenyl)-5-hydroxy-2-methylpentanoate) wasdissolved in tetrahydrofuran (450 mL) and methanol (150 mL). Lithiumhydroxide (1.4 M, 149 mL, 208 mmol) was added, and the solution wasstirred at room temperature for 24 hours. The mixture was concentratedunder vacuum and the residue was redissolved in ethyl acetate. Aqueous1N hydrochloric acid was added with stirring until the aqueous layer hada pH of about 1.

The layers were separated and the organic phase was washed with brine,dried over magnesium sulfate, filtered and concentrated. The materialwas then dissolved in 200 mL of anhydrous toluene and treated withpyridiniump-toluenesulfonate (PPTS, 0.784 g, 3.12 mmol). The reactionwas heated to reflux under Dean-Stark conditions until the seco-acid wasconsumed (about 2 hours). The reaction was cooled to room temperatureand washed with saturated sodium bicarbonate (50 mL) and brine (50 mL).The solution was dried over sodium sulfate, filtered and concentrated.The crude material was purified by flash chromatography on silica gel(120 g column; eluting with 100% dichloromethane). The(3S,5R,6R)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-oneand(3R,5R,6R)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-onewere obtained as a white solid with an approximate 94:6 enantiomericratio and a 7:3 mixture of methyl diastereomers. ¹H NMR (400 MHz, CDCl₃,δ ppm): 7.22-6.98 (series of m, 5H), 6.91 (dt, J=7.4, 1.2 Hz, 0.3H),6.81 (m, 2H), 6.73 (dt, J=7.6, 1.4 Hz, 0.7H), 5.76 (d, J=4.1 Hz, 0.3 H),5.69 (d, J=4.7 Hz, 0.7H), 3.67 (dt, J=6.6, 4.3 Hz, 0.3H), 3.55 (td,J=7.8, 4.7 Hz, 0.7 H), 2.96 (d of quintets, J=13.5, 6.7 Hz, 0.7 H), 2.81(m, 0.3 H), 2.56 (dt, J=14.3, 8.0 Hz, 0.7 H), 2.32 (dt, J=13.69, 7.0 Hz,0.3 H), 2.06 (ddd, J=13.7, 8.4, 4.1, 0.3 H), 1.85 (ddd, J=14.1, 12.5,7.4, 0.7 H), 1.42 (d, J=7.0 Hz, 0.9 H), 1.41 (d, J=6.7 Hz, 2.1H). MS(ESI)=357.0 [M+23]+. [α]_(D) (22° C., c=1.0, CH₂Cl₂)=−31.9°; m.p. 98-99°C.

Step D.(3S,5R,6R)-3-Allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one

A solution of(3S,5R,6R)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-oneand(3R,5S,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one(4.5 g, 13.4 mmol) (from Step C) and allyl bromide (3.48 mL, 40.3 mmol)in tetrahydrofuran (22 mL) at −35° C. (acetonitrile/dry ice bath) wastreated with a solution of lithium bis(trimethylsilyl)amide intetrahydrofuran (1.0 M, 17.45 mL, 17.45 mmol). The reaction was allowedto warm to −5° C. over 1 hour and then was quenched with 50% saturatedammonium chloride. The reaction was diluted with 100 mL of ethyl acetateand the layers were separated. The organic phase was washed with brine,dried over magnesium sulfate, filtered and concentrated under vacuum toafford the title compound as a white solid upon standing under vacuum.Chiral SFC (92% CO₂, 8% methanol (20 mM ammonia), 5 mL/min, PhenomenexLux-2 column (Phenomenex, Torrance, CA), 100 bar (10,000 kPa), 40° C., 5minute method) was used to determine that the compound had anenantiomeric ratio of 96:4. (Major enantiomer: title compound, retentiontime=2.45 minutes, 96%; minor enantiomer (structure not shown, retentiontime=2.12 min, 4%). The(3S,5R,6R)-3-allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-onewas recrystallized by addition to heptane (4.7 g slurried in 40 mL) atreflux followed by dropwise addition of 1.5 mL of toluene to solubilize.The solution was cooled to 0° C. The resulting white solid was filteredand rinsed with 20 mL of cold heptane to afford a white powder. ChiralSFC (92% CO₂, 8% methanol, Phenomenex Lux-2 column, same method asabove) indicated an enantiomeric ratio of 99.2:0.8. (major enantiomer,2.45 min, 99.2%; minor enantiomer: 2.12 min, 0.8%). ¹H NMR (400 MHz,CDCl₃, S ppm): 7.24 (ddd, J=8.0, 2.0, 1.2 Hz, 1H), 7.20-7.15 (series ofm, 3H), 6.91 (t, J=2.0 Hz, 1H), 6.78 (br d, J=7.6 Hz, 1H), 6.60 (m, 2H),5.84 (ddt, J=17.6, 10.2, 7.4 Hz, 1H), 5.70 (d, J=5.3 Hz, 1H), 5.21-5.13(series of m, 2H), 3.82 (dt, J=11.7, 4.5 Hz, 1H), 2.62 (ABX J_(AB)=13.7Hz, JAx=7.6 Hz, 1H), 2.53 (ABX, J_(AB)=13.9 Hz, J_(BX)=7.2 Hz, 1H). 1.99(dd, J=14.1, 11.9 Hz, 1H), 1.92 (ddd, J=13.9, 3.9, 1.2 Hz, 1H). ¹³C NMR(CDCl₃, 100 MHz, δ ppm): 175.9, 140.2, 134.5, 134.3, 134.0, 132.2,129.8, 128.6, 128.0, 127.9, 127.8, 126.4, 119.9, 83.9, 44.5, 42.4, 40.7,31.8, 26.1. MS (ESI)=375.2 [M+H]⁺. IR=1730 cm⁻¹. [α]_(D) (24° C., c=1.0,CH₂Cl₂)=−191°. m.p. 111-114° C.

Alternative Procedure for Preparing(3S,5R,6R)-3-allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one

Step 1: Isopropyl4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate

A solution of 2-(3-chlorophenyl)-1-(4-chlorophenyl)ethanone (Step A)(67.4 Kg, 255 mol) in THE (325 L) was dried azeotropically to achieve awater content by Karl Fisher of 0.05 wt %. Methyl methacrylate (25.8 Kg,257 mol) was added to the solution and the mixture was heated to 45° C.A solution of potassium tert-butoxide (20 wt % in THF, 14.3 Kg, 25 mol)was added over the course of 30 minutes and the mixture was agitated for6 h. The mixture was then cooled to 10° C. and an aqueous solution ofcitric acid monohydrate (20 wt %, 35 L) was added in less than 5minutes. Isopropyl acetate (400 L) and an aqueous sodium chloridesolution (20 wt %, 300 L) were added. The mixture was agitated for 15minutes and the phases were separated. The organic phase was distilledunder reduced pressure to generate a distillate volume of 560 L whilesimultaneously adding isopropanol (350 L) to produce a solution ofmethyl 4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate inisopropanol (54 wt %, 140 kg total solution mass). The solution had awater content of 0.01 wt % by Karl Fisher. Additional isopropanol (420L) and sulfuric acid (53 Kg, 535 mol) were added to the solution. Themixture was warmed to reflux and agitated for 12 h, during which time200 L of solvent were distilled and 200 L of fresh isopropanol wereadded to the mixture. The mixture was then cooled to 20° C. and water(180 L) was added over the course of 30 minutes. Isopropyl acetate (270L) was added and the mixture was agitated for 30 minutes. The phaseswere separated and the aqueous phase was extracted using isopropylacetate (100 L). The combined organic phases were washed with water (200L) four times. The organic phase was distilled under reduced pressure togenerate a distillate volume of 500 L while simultaneously addingisopropanol (50 L) to provide a solution of isopropyl4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate inisopropanol (60 wt %, 134 kg total solution mass). The solution had awater content of 0.02 wt % by Karl Fisher. The isopropyl4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate wasobtained in 81% overall yield as a roughly 1:1 mixture ofdiastereoisomers. ¹H NMR (400 MHz, CDCl₃, δ ppm): 7.70-7.80 (m, 2H),7.22-7.28 (m, 2H), 7.00-7.18 (series of m, 4H), 4.78-4.96 (m, 1H),4.42-4.50 (m, 1H), 2.02-2.30 (m, 2H), 1.80-1.95 (m, 1H), 0.99-1.19 (m,15H).

Step 2.(3S,5R,6R)-3-Allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one

To a degassed solution of isopropyl4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate (fromStep 1) in isopropanol (60 wt %, 252 kg total solution mass, 151 Kg ofisopropyl ester starting material, 385 mol) was added degassedisopropanol (900 L) and potassium tert-butoxide (13 Kg, 116 mol). Aseparately prepared degassed solution of (S)-RUCY®-XylBINAP (also knownas RuCl[(S)-diapena][(S)-xylbinap] (230 g, 0.2 mol, catalyst, TakasagoInternational Corporation, Rockleigh, NJ) in isopropanol (25 L). Themixture was purged four times with hydrogen at 5 bars (500 kPa) andagitated at 20° C. for 5.5 h. The hydrogen pressurization wasdiscontinued and the mixture was degassed with nitrogen. Tetrahydrofuran(460 L) was added to the mixture. A solution of lithium hydroxide (24Kg, 576 mol) in water (305 L) was added to the reaction mixture over thecourse of 40 minutes and the resultant mixture was agitated at 20° C.for 24 h. A solution of concentrated hydrochloric acid (79.3 Kg, 11.4 M,740 mol) in water (690 L) was added to the mixture over the course of 2h. Toluene (580 L) was added, the mixture was then agitated for 30minutes, and the phases were separated. The aqueous phase was extractedusing toluene (700 L). The combined organic layers were washed with anaqueous solution of sodium chloride (25 wt %, 700 Kg). The organic phasewas distilled at atmospheric pressure and 100° C. to generate adistillate volume of 2700 L while simultaneously adding toluene (800 L).Less than 0.05 wt % isopropanol or water (by Karl Fisher) remained inthe mixture after this solvent exchange. Carbonyl diimidazole (59 Kg,365 mol) was added to the toluene solution over the course of 2 h andthe mixture was agitated at 20° C. for two additional hours. The mixturewas then cooled to 10° C. and a solution of orthophosphoric acid (72 Kg,545 mol) in water (400 L) was added over the course of 1 h, whilemaintaining the temperature of the mixture below 20° C. The mixture wasagitated for 30 minutes, the phases were separated and the organic layerwas washed with an aqueous solution of sodium chloride (25 wt %, 484Kg). Toluene (400 L) was distilled at atmospheric pressure and at 110°C. After cooling of the solution to 20° C., tetrahydrofuran (500 L) wasadded and the water content by Karl Fisher was measured to be 0.03 wt %.The product solution was cooled to −10° C. and a solution allyl bromide(66.8 Kg, 552 mol) in tetrahydrofuran (50 L) was added. A lithiumhexamethyldisilazide solution in toluene (255 Kg, 26 wt %, 492 mol) wasadded over the course of 6 h and the mixture was stirred at −10° C. for1 h. The mixture was warmed to 0° C. and an aqueous solution oforthophosphoric acid (40 wt %, 400 mol) was added over the course of 3h. The mixture was warmed to 20° C. Water (200 L) and dichloromethane(400 L) were added. The mixture was agitated for 15 minutes and thephases were separated. The solution was distilled at atmosphericpressure and 100° C. to generate a distillate volume of 1350 L and theresidual toluene in the mixture was measured to be 9.8 wt %. The mixturewas cooled to 70° C. Diisopropyl ether (85 L), water (26 L), andisopropanol (65 L) were added. The mixture was cooled to 35° C.,agitated for 9 h, cooled to 30° C., and filtered. The filtered materialwas washed three times with heptane (80 L). The solids were dried at 55°C. for 48 hours to provide 90.1 Kg of(3S,5R,6R)-3-allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-onein 63% overall yield. Chiral HPLC indicated an enantiomeric ratio of99.95:0.05.

Example 2: Differences Between First-In-Human Process and CommercialProcess of Making Compound A

A gram-scale synthesis of DLAC has previously been reported. See, Sun etal., J. Med. Chem. 2014, 57, 1454. Based on this work, Compound A wasprepared by the first-in-human (FIH) synthetic process illustrated inScheme 1. Intermediate OXOS was used as a regulatory starting materialfor this process. Ring-opening of DLAC using excess L-valinol (3equivalents) at elevated temperature afforded amide ABA, which wasextracted in dichloromethane. Excess L-valinol was removed using aqueoushydrochloric acid washes and the product solution was carried into thesubsequent step without purification. Reduction of the amounts ofL-valinol used in this transformation was identified as a developmentobjective going forward in view of the high cost of this raw material.Notably, the preparation of ABA analogues ABA1 or ABA2 from thecorresponding DLAC analogues DLAC1 or DLAC2, which bear side-chainscontaining a group of the same oxidation state as the carboxylic acid ofCompound A, was not successful due to the formation of the undesiredsuccinimides SUC1 or SUC2. Considering the similar rates observed forthe formation of the desired products ABA1-ABA2 and their transformationto the side-products SUC1-SUC2, it was not possible to isolate theamides ABA1-ABA2 in acceptable yields.

The oxoiminium salt OXOS was prepared from ABA by double activation withtwo equivalents of toluenesulfonic anhydride and 2,6-lutidine atelevated temperature. The cation thus prepared was isolated as a2-naphthylsulfonic acid salt, which offered satisfactory impurityremoval properties. Identifying an alternative reagent totoluenesulfonic anhydride (TsO₂) was contemplated for multiple reasons,including the need to eliminate the long lasting tosylate intermediateDHO-OTs, which underwent slow transformation to OXOS at elevatedtemperature (120° C.). This intermediate (DHO-OTs) is an alkylatingagent and thus a potentially mutagenic impurity. One possible optionconsidered was to isolate the crystalline intermediate DHO (Scheme 3) toincrease control over the effective removal of impurities for amanufacturing sequence. However, this necessitated the use of a reagentwhich allowed for the selective chemoselective activation of the primaryalcohol of ABA in the presence of the secondary benzylic alcohol.Sulfonic anhydrides reagents did not offer this advantage.

The preparation of SUL from OXOS was carried out by treatment of theOXOS with isopropylsulfinic acid in the presence of sodium t-butoxide.This transformation proceeds via reversible formation of adiastereomeric pair of sulfinate intermediates (SULFI) and subsequentrearrangement to the thermodynamic product SUL, which is crystallizedfrom acetonitrile and water (Scheme 4). The ALC side product formedirreversibly under these conditions in the presence of water.Isopropylsulfinic acid, an oil at 20° C., was prepared fromisopropylmagnesium chloride and isolated after an aqueous work-up.Azeotropic drying of this reagent was necessary prior to use in theformation of SUL to avoid generation of the undesired ALC side-productin large quantities. However, isopropyl sulfinate was observed todecompose via disproportionation upon drying and thus this unitoperation was avoided. Consequently, the discovery of a stablecrystalline salt of isopropylsulfinic acid which was stable under dryingconditions and which may be designated as a commercial regulatorystarting material was sought. Alternatively, a process for the in situpreparation of a sulfinic acid salt from isopropyl magnesium chloridewithout an aqueous work-up and further reaction with OXOS wasconsidered.

Oxidation of the alkene group of SUL was carried out via treatment withcatalytic ruthenium chloride (2 mol %) and excess sodium periodate (5equivalents). The crude product was isolated as a crystalline ethanolsolvate. Several features of this step were observed to be undesirable.First, the heavy metal used in this step had to be scavenged, which wasaccomplished using a DARCO-G resin for the first-in-human delivery.Additionally, multiple equivalents of sodium periodate were necessary tocarry out this process and the reagent had to be charged to the reactionvessel in portions to minimize impurity formation. A complex downstreamtreatment protocol (extractions and filtrations) was required to removethe large amounts of salts utilized for the transformation. Further,multiple dimeric impurities were generated in this transformation step,which made it challenging to control the purity of the drug substance.The use of an ethanol solvate of Compound A as a crystalline controlpoint was problematic and was only moderately effective at removal ofthe impurities present in the mixture. In addition, the crystallizationprocess had to be conducted as an evaporative process due to the lowethanol concentration (5% v/v) which was necessary to alleviate highmother liquor losses during filtration. The use of ethanol in thecrystallization process was also observed to reduce the robustness ofthe process due to the undesired formation of the corresponding ethylester at temperatures above 30° C. and the difficulty experienced inremoval of the ethyl ester from the desired ethanol solvate.

Similarly, when methanol was used in the crystallization of Compound A,the formation of the corresponding methyl ester at elevatedtemperatures, which was also difficult to isolate away from the drugsubstance, significantly reduced the viability of this route forcrystallization, especially when operating on multigram scale. Thus, thedevelopment of a more consistent and environmentally friendly oxidationprocess for the preparation of Compound A from SUL as well as thegeneration of a robust strategy for isolating the drug substance thatexhibits the effective control of critical attributes were sought aspart of a commercially viable process.

TABLE 1 Modifications to the FIH Process in the Commercial Process toPrepare Compound A CP1 Process Step FIH Process Commercial ProcessSolution ABA from DLAC Three equivalents of L-Valinol used Reduction ofL-Valinol equivalents to two OXOS from ABA DHO is not isolatedReplacement of TS₂O with a chemoselective reagent enabling isolation ofDHO OXOS from ABA PMI and long-lasting intermediate DHO- Replacement ofTS₂O with a reagent OTs are formed enabling the formation of anintermediate undergoing rapid conversion to OXOS SUL from OXOSIsopropylsulfinic acid is a liquid at 20° C. Discovery of a crystallinesalt of and is unstable to azeotropic drying isopropylsulfinic acid saltthat is conditions stable under drying conditions Compound A from SULRuthenium catalyst is used in the last step Change of reagents for thelast step Compound A from SUL Excess (5 equiv) sodium periodate is usedin Change of reagents for the last step last step Isolation of CompoundThe isolation is only moderately effective at Discovery of a salt ofCompound A A as an ethanol solvate removal of impurities and is not wellsuited well suited to crystallization design for crystallization designand having superior impurity removal properties Isolation of CompoundThe isolation is poorly effective at removal Develop a newcrystallization of the A of the undesired corresponding methyl esterdrug substance, Compound A, which which can form in the crystallizationsystem is free from impurity formation used (MeOH/H₂O)

Example 3: Development of a Commercial Process to Prepare theIntermediate OXOS

The thermal amidation of DLAC to ABA with L-valinol proceeded through amultistep mechanism via intermediate ester EST (Scheme 5). The initialtransesterification of DLAC to EST was determined to be a reversibleprocess (k₁>k⁻¹ with 2 equivalents of L-valinol) leading to a build-upof EST prior to rearrangement to the amide product ABA. Upon performingthe reaction at 60° C., rapid conversion of DLAC to EST is observed atthe start of the reaction followed by slow conversion of EST to ABA overthe course of several days (k₁>k₂) (FIG. 1 ). At elevated temperatures(115° C.) (FIG. 2 ), the rearrangement of EST to the more stable ABA isfaster, resulting in an increase in the overall rate of the reaction byincreasing the concentration of EST.

The FIH process utilized a thermal melt with 3 equivalents of L-valinolto ensure rapid conversion of DLAC to ABA at 110° C. Consistent with ourmechanistic understanding of this transformation, decreasing L-valinolloading (from 3 equivalents to 2 equivalents) resulted in a decrease inthe overall rate of the reaction since the conversion of DLAC to EST(k₁) directly impacts the relative concentration of EST. When 2equivalents of L-valinol was used, the reaction was observed to require72 hours to reach conversion at 115° C., while employing toluene (1volume) to ensure reaction homogeneity. This longer processing time,however, may be considered justifiable based on significant costreductions. Elimination of excess L-valinol was achieved by the additionof toluene (4 volumes) and subsequent washing of the organic mixturewith an aqueous hydrochloric acid solution. The resultant organicsolution was azeotropically dried and polish filtered to afford ABA in91% assay yield as a 28 wt % solution in toluene containing 2.7 LC area% of DHO, 1.0 LC area % of starting material DLAC, and 1.0 LC area % ofEST. Thermolysis of ABA to prepare directly DHO at higher temperaturesled to complex mixtures of products.

The isolation of intermediate DHO provided an additional opportunity toremove impurities from the process stream and to strengthen the overallcontrol strategy to deliver a drug substance for market application.Paramount to this strategy was the identification of conditions thatwould untether the dehydrative double-cyclization of ABA to OXOS intotwo distinct mono-cyclization reactions through the development of achemoselective activation of the primary alcohol of ABA (conditions A)that would enable the isolation of DHO in crystalline form (Scheme 6).

Sulfonyl chloride and sulfonic anhydride reagents were found to beunselective in discriminating between the primary and secondary alcoholsof ABA and were difficult to procure as anhydrous reagents. Furthermore,the use of acid catalysts also afforded complex mixtures of products.However, a Vilsmeier salt reagent, methoxymethylene-N,N-dimethyliminiummethyl sulfate, successfully achieved the desired selectivity. Thisreagent was easily prepared with no special precautions taken to excludemoisture and it can be stored at 20° C. for several months with noerosion in titer. Additionally, it exhibited milder reactivity andimproved chemoselectivity compared to the common halide-derivedVilsmeier salt chloromethylene-N,N-dimethyliminium chloride and alsoavoided the formation of alkyl halide side-products. The formation ofDHO from ABA using methoxymethylene-N,N-dimethyliminium methyl sulfatein toluene was evaluated in the presence of various mild inorganic basesat 25° C. and the conversion to DHO was recorded (Scheme 7). Thereaction was observed to perform best with KOAc, but NaOAc waspreferred, considering its low hygroscopicity and cost.

DHO assay Conversion Base yield % time (hr) KOAc 94.6 2 NaOAc 91.9 2LiOAc 86.5 20 K₂CO₃ 70.4 16

The desired chemoselectivity of this transformation is achieved throughthe unique ability of methoxymethylene-N,N-dimethyliminium methylsulfate to undergo dynamic transesterification with alcohols through thegeneration of labile imidate intermediates. This reversibility wasinvestigated in the activation of 4-chlorobenzyl alcohol (CHA) with thedeuterated reagent DEU to generate imidate IMI, which was found toequilibrate at a 2.5/1 ratio of CHA/IMI (Scheme 8). Based on thisobservation, it is proposed that the IMABA exists in low concentrationsduring the reaction and undergoes a rapid intramolecular displacementwith the pendant amide to generate oxazoline DHO (Scheme 8). Any imidateformed by derivatization of the secondary alcohol group of the ABA groupdoes not undergo further cyclization to OXOS at the operating reactiontemperature (30° C.).

Equilibrium solubility measurements were gathered for DHO in varioussolvents. It was observed that all values obtained were above 20 mg/mLat 20° C. (including heptane) except for water (<0.1 mg/mL), which wasthus selected as an anti-solvent. Acetonitrile was selected as a solventfor crystallization as it resulted in the facile removal of impuritieswhen in combination with water. A curve showing solubility values atdifferent time points in the crystallization process is presented inFIG. 3 . Using this protocol, crystalline DHO was isolated in 88% yieldfrom DLAC in a >98 LC area % (Scheme 9).

A Bruker D8 powder X-ray diffractometer was used to acquire reflectionPXRD pattern of the crystalline DHO (FIG. 17 ) and was equipped with aBraun detector and a Cu-Kα radiation source operating in Bragg-Brentanoreflection geometry. The obtained 2-theta (2θ) values were generallyaccurate to within an error of ±0.2°. The samples were generallyprepared without any special treatment other than the application ofslight pressure to achieve a flat surface. Samples were measureduncovered unless otherwise noted. Operating conditions included a tubevoltage of 40 kV and current of 40 mA. A variable divergence slit wasused with a 35 window. The step size was 0.019 020 with a step time of35.2 seconds. The sample was static during the measurement.

The peaks listed in Table 2 were identified in the PXRD pattern ofcrystalline DHO.

TABLE 2 PXRD peaks for crystalline DHO Peak Angle d Value Intensity Rel.Intensity 1 6.3 14.12344 753 14.90% 2 7.3 12.15811 3080 61.10% 3 8.510.43913 2521 50.00% 4 10.0 8.86434 871 17.30% 5 10.5 8.42517 569 11.30%6 11.0 8.03156 934 18.50% 7 11.5 7.6782 448 8.90% 8 12.8 6.9125 61812.30% 9 13.4 6.61879 2598 51.50% 10 14.5 6.11557 4427 87.80% 11 14.85.98483 474 9.40% 12 15.2 5.84027 331 6.60% 13 15.9 5.57383 5042 100.00%14 15.8 5.59708 4060 80.50% 15 17.0 5.22058 757 15.00% 16 17.5 5.0574749 14.80% 17 17.8 4.97509 613 12.20% 18 18.4 4.82391 662 13.10% 19 18.84.72167 937 18.60% 20 19.0 4.67741 969 19.20% 21 19.7 4.49805 165 3.30%22 19.9 4.46033 169 3.30% 23 20.7 4.28732 168 3.30% 24 21.2 4.18605 3947.80% 25 21.3 4.16028 399 7.90% 26 22.0 4.03425 963 19.10% 27 22.43.96797 741 14.70% 28 23.1 3.84953 3121 61.90% 29 23.6 3.77436 66513.20% 30 24.2 3.67661 840 16.70% 31 24.9 3.56615 357 7.10% 32 25.73.46767 455 9.00% 33 26.3 3.38729 262 5.20% 34 27.0 3.30081 434 8.60% 3528.3 3.1469 248 4.90% 36 28.7 3.11305 62.8 1.20% 37 29.3 3.04435 1673.30% 38 29.7 3.00202 118 2.30% 39 30.8 2.9015 135 2.70% 40 31.4 2.84914381 7.50% 41 31.8 2.80958 113 2.20% 42 33.0 2.71451 159 3.20% 43 34.22.62156 161 3.20% 44 35.8 2.50313 201 4.00% 45 37.0 2.42816 39.5 0.80%46 37.5 2.39507 112 2.20%

Having untethered the double dehydrative cyclization of ABA to OXOS,development of a method to convert DHO to OXOS was needed.Methanesulfonic anhydride (Ms₂O) was found to provide a fasterconversion to OXOS compared to Ts₂O, as potentially mutagenic mesylateintermediate DHO-OMs is completely consumed at 75° C. in 10 hours. Thisimprovement is likely due to the reduced steric hindrance experienced inthe transition state leading from DHO-OMs to OXOS compared to thatinvolved in the cyclization of DHO-OTs to OXOS. The transformation wasfound to proceed well with 2,6-lutidine as a base in toluene.Nucleophilic organic bases and inorganic bases undesirably affordedcomplex mixtures of products. The mesylate salt of OXOS generated duringthe transformation is poorly soluble in toluene and forms a separateliquid layer as the reaction progresses. To enable further processing,it is necessary to dilute the reaction mixture with dichloromethane (8V)prior to removal of the mesylate salts using aqueous sulfuric acidwashes. Salt metathesis with aqueous sodium 1-naphthalenesulfonate wasfollowed by distillation of dichloromethane, leading to thecrystallization of a 1-naphthalenesulfonate toluene hemi-solvate OXOSsalt in 90% yield, 99.5 LC area %, and 99.7 wt % from DHO (Scheme 10).

The following experimental procedures illustrate the preparation ofOXOS.

N,N-Dimethylformamide dimethyl sulfate adduct: A 500-mL Atlas reactoraffixed with a reflux condenser and overhead stirring shaft was chargedwith dimethyl sulfate (200.0 mL, 2.11 mol, 1.0 equiv.) under a nitrogenatmosphere. The contents of the reactor were warmed to 60° C. DMF (200.0mL, 2.56 mol, 1.2 equiv.) was added dropwise over 60 minutes (3.3mL/min). Upon completion of addition, the reaction was stirred for 2hours at 60° C. Upon completion of the reaction, the reaction was cooledto room temperature to afford the N,N-dimethylformamide dimethyl sulfateadduct as a solution in residual DMF (402.6 g, 2.02 mol, 95.8% assayyield, 82.8 wt % in DMF).

(S)-2-((2R,3R)-2-(3-chlorophenyl)-3-(4-chlorophenyl)-3-hydroxypropyl)-N—((S)-1-hydroxy-3-methylbutan-2-yl)-2-methylpent-4-enamide(ABA): A 5-L ChemGlass reactor affixed with a reflux condenser andoverhead stirring shaft was charged with(3S,5R,6R)-3-allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one(DLAC) (201.8 g, 0.53 mol, 98.6 wt %, 1.0 equiv.), L-valinol (110.8 g,1.06 mol, 2.0 equiv.), and toluene (205 mL, 1 mL/g) under a nitrogenatmosphere. The contents of the reactor were heated under reflux (115°C.) with constant stirring for 72 hours. Upon completion of thereaction, the reaction was cooled to room temperature and diluted withtoluene (800 mL, 5 mL/g). The reaction was quenched by portion wiseaddition of 1N HCl (1000 mL, 5 mL/g). The phases were split and theorganic layer was subsequently washed twice with brine (2×400 mL, 2mL/g). The organic phase was dried over magnesium sulfate, filteredthrough a polish filter (coarse porosity) while rinsing with toluene,and concentrated to a volume of approximately 800 mL to afford ABA as asolution in toluene (229.4 g, 0.48 mol, 90.5% assay yield, 27.9 wt % intoluene). ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm: 7.05-7.19 (m, 5H), 6.95(d, J=8.50 Hz, 2H), 6.84 (d, J=7.67 Hz, 1H), 5.85 (d, J=8.09 Hz, 1H),5.57 (ddt, J=17.13, 9.98, 7.28, 7.28 Hz, 1H), 4.91-5.03 (m, 2H), 4.71(d, J=4.77 Hz, 1H), 3.66 (br s, 1H), 3.57-3.63 (m, 1H), 3.51-3.53 (m,1H), 3.42-3.46 (m, 1H), 3.19 (br s, 1H), 2.97 (dt, J=7.93, 4.95 Hz, 1H),2.36 (dd, J=13.89, 7.05 Hz, 1H), 2.13 (dd, J=14.62, 4.87 Hz, 1H),1.96-2.01 (m, 1H), 1.87-1.92 (m, 1H), 1.71-1.82 (m, 1H), 1.10 (s, 3H),0.88 (d, J=7.05 Hz, 3H), 0.86 (d, J=7.05 Hz, 3H). ¹³C NMR (101 MHz,CHLOROFORM-d) δ ppm: 177.47, 142.83, 140.46, 133.79, 133.67, 133.00,129.49, 129.12, 127.96, 127.93, 127.68, 126.88, 118.64, 75.91, 63.44,56.94, 49.51, 45.17, 42.13, 39.59, 29.06, 24.07, 19.40, 18.72.

(1R,2R,4S)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-4-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)-4-methylhept-6-en-1-ol(DHO): A 5-L ChemGlass reactor affixed with a reflux condenser andoverhead stirring shaft was charged with(S)-2-((2R,3R)-2-(3-chlorophenyl)-3-(4-chlorophenyl)-3-hydroxypropyl)-N—((S)-1-hydroxy-3-methylbutan-2-yl)-2-methylpent-4-enamide(ABA) (229.4 g, 0.48 mol, 27.9 wt % in toluene, 1.0 equiv.) and toluene(1145 mL, 5 mL/g) under a nitrogen atmosphere. (Note: since ABA isobtained as a stock solution in toluene containing 685 mL of residualtoluene, the amount of additional toluene needed is 460 mL). Thecontents of the reactor were warmed to 30° C. NaOAc (48.3 g, 0.59 mol,1.2 equiv.) and N,N-dimethylformamide dimethyl sulfate adduct (174.1 g,0.72 mol, 82.8 wt %, 1.5 equiv.) were sequentially added to thereaction. After stirring at 30° C. for 2 hours, the reaction was cooledto room temperature. The reaction was quenched with sat. aq. NH₄Cl (750mL, 3 mL/g) and H₂O (500 mL, 2 mL/g). The phases were split and theorganic layer was subsequently washed twice with brine (2×750 mL, 3mL/g). The organic phase was dried over magnesium sulfate, filteredthrough a polish filter (coarse porosity) while rinsing with toluene,and concentrated in vacuo. The crude residue was recrystallized fromMeCN:H₂O (50:50) to afford DHO as a white crystalline solid (206.5 g,0.45 mol, 87.7% yield over 2 steps corrected by wt %). ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm: 7.07-7.21 (m, 5H), 6.99 (d, J=8.29 Hz, 2H), 6.88(d, J=7.10 Hz, 1H), 5.44-5.55 (m, 1H), 4.83-4.97 (m, 2H), 4.73 (d,J=5.60 Hz, 1H), 4.42 (br s, 1H), 4.03 (dd, J=8.91, 7.67 Hz, 1H),3.63-3.76 (m, 2H), 3.15-3.21 (m, 1H), 2.35 (dd, J=13.89, 7.26 Hz, 1H),2.13-2.18 (m, 1H), 2.07-2.12 (m, 1H), 1.84 (dd, J=14.72, 8.09 Hz, 1H),1.48-1.60 (m, 1H), 1.09 (s, 3H), 0.94 (d, J=6.63 Hz, 3H), 0.82 (d,J=6.63 Hz, 3H). ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm: 171.99, 143.48,140.41, 133.74, 133.35, 132.92, 129.55, 129.09, 128.24, 127.84, 127.75,126.75, 118.33, 76.63, 71.80, 69.84, 49.36, 42.13, 39.72, 38.61, 32.48,24.20, 19.10, 18.26.

(3S,5S,6R,8S)-8-allyl-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-isopropyl-8-methyl-2,3,5,6,7,8-hexahydrooxazolo[3,2-a]pyridin-4-iumnaphthalene-1-sulfonate toluene hemisolvate (OXOS): A 5-L ChemGlassreactor affixed with a reflux condenser and overhead stirring shaft wascharged with(1R,2R,4S)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-4-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)-4-methylhept-6-en-1-ol(DHO) (199.3 g, 0.40 mol, 93.5 wt %, 1.0 equiv.) and toluene (1000 mL, 5mL/g) under a nitrogen atmosphere. Methanesulfonic anhydride (88.2 g,0.49 mol, 1.2 equiv.) and 2,6-lutidine (95.0 mL, 0.82 mol, 2.0 equiv.)were sequentially added to the reaction. The contents of the reactorwere heated to 75° C. with constant stirring for 16 hours. Uponcompletion of the reaction, the reaction was cooled to room temperatureand diluted with dichloromethane (1600 mL, 8 mL/g). The reaction wasquenched with a solution of conc. H₂SO₄ (45.0 mL, 0.82 mol, 2.0 equiv.)in H₂O (955 mL, 5 mL/g). The phases were split and the organic layer wassubsequently washed twice with an aqueous solution of sodium1-naphthalenesulfonate (2×72.5 g, 0.31 mol, 0.75 equiv.) in H₂O (2×800mL, 4 mL/g). The organic phase was dried over sodium1-naphthalenesulfonate (10.0 g, 0.04 mol, 0.1 equiv.), filtered througha polish filter (coarse porosity) while rinsing with dichloromethane,and concentrated in vacuo. The crude residue was recrystallized fromtoluene to afford OXOS as an off-white crystalline solid (260.1 g, 0.37mol, 90.0% yield corrected by wt %). ¹H NMR (400 MHz, CHLOROFORM-d) δppm: 9.14 (d, J=8.50 Hz, 1H), 8.35 (dd, J=7.26, 1.24 Hz, 1H), 7.86 (t,J=8.71 Hz, 2H), 7.57 (t, J=7.70 Hz, 1H), 7.43-7.50 (m, 2H), 7.13-7.39(m, 7.5H), 7.03-7.10 (m, 3H), 6.07 (d, J=11.20 Hz, 1H), 5.80 (ddt,J=17.00, 9.90, 7.39, 7.39 Hz, 1H), 5.51 (t, J=9.74 Hz, 1H), 5.26-5.34(m, 2H), 4.76 (ddd, J=10.37, 4.66, 2.18 Hz, 1H), 4.62 (dd, J=9.12, 4.77Hz, 1H), 3.51-3.60 (m, 1H), 2.86 (t, J=13.68 Hz, 1H), 2.65-2.71 (m, 1H),2.55-2.60 (m, 1H), 2.35 (s, 1.5H), 1.95 (dd, J=13.89, 3.52 Hz, 1H), 1.52(s, 3H), 0.54-0.67 (m, 7H). ¹³C NMR (101 MHz, CHLOROFORM-d) δ ppm:183.28, 142.16, 140.01, 137.71, 135.89, 134.15, 134.12, 133.28, 132.15,130.38, 130.30, 129.95, 129.62, 129.43, 129.06, 128.90, 128.34, 128.09,127.92, 127.66, 127.41, 127.18, 126.44, 125.88, 125.63, 125.48, 125.16,124.28, 121.20, 73.14, 67.27, 67.06, 43.64, 43.01, 38.67, 38.56, 26.64,22.13, 21.32, 18.08, 13.74.

Alternatively, the intermediate DHO-OMs can be separated and purifiedbefore conversion to OXOS.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm: 7.31 (d, J=8.4 Hz, 2H), 7.24-7.18(m, 2H), 7.16 (s, 1H), 7.08 (d, J=8.2 Hz, 2H), 7.07-7.01 (m, 1H),5.59-5.43 (m, 2H), 5.01-4.83 (m, 2H), 3.84 (dd, J=8.1, 9.5 Hz, 1H),3.55-3.45 (m, 1H), 3.42-3.34 (m, 1H), 3.24-3.13 (m, 1H), 2.46 (s, 3H),2.39-2.28 (m, 1H), 2.28-2.14 (m, 1H), 1.98 (br dd, J=7.8, 13.6 Hz, 1H),1.72 (dd, J=2.4, 14.3 Hz, 1H), 1.26 (br s, 1H), 1.06 (s, 3H), 0.88 (d,J=6.7 Hz, 3H), 0.71 (d, J=6.7 Hz, 3H). ¹³C NMR (101 MHz, CHLOROFORM-d) δppm: 169.69, 141.54, 135.61, 134.98, 133.92, 133.43, 129.82, 129.30,128.81, 128.47, 127.82, 127.34, 118.21, 87.02, 77.22, 69.78, 47.99,44.57, 39.96, 39.31, 38.46, 32.80, 21.85, 19.40, 18.26.

Example 4: Development of a Commercial Process to Prepare PenultimateIntermediate SUL

The treatment of OXOS with an isopropylsulfinate salt at elevatedtemperatures lead to the formation of the diastereomeric pair ofsulfinate esters SULFI (Scheme 4) which rearranged to the morethermodynamically stable product SUL. This type of sulfinate-sulfonerearrangement has been described in conventional processes to occur viaan ion pair formation and a recombination mechanism for benzhydrylsulfinate esters. However, in present process, the results of across-over experiment, shown in Scheme 11, reveals that therearrangement involves dissociated ions. Considering that OXOS reactsquantitatively with water at temperatures above 70° C., there is ampleopportunity for the alcohol ALC to be generated. Unless OXOS can bere-generated from ALC, water must be rigorously excluded from thereaction mixture. One path for achieving this objective is to prepare asalt of isopropylsulfinic acid which is stable to azeotropic dryingconditions, can be isolated in high purity, and efficiently reacts withOXOS to generate SUL.

After the evaluation of several isopropylsufinic acid salt candidates toachieve this objective, including the lithium, sodium, potassium,magnesium and ammonium salts, the calcium sulfinate dihydrate salt stoodout as a stable and crystalline species. This salt was prepared from thereaction of isopropyl magnesium chloride with sulfur dioxide (Scheme12), leading to the formation of isopropylsulfinic acid after an aqueoushydrochloric acid quench. This material was treated with calciumacetate, which allowed for the isolation of the calciumisopropylsulfinate dihydrate (CALID) via a reactive crystallization.While a hydrate is not the ideal species for use in the preparation ofSUL considering the water sensitivity of the process described above,the calcium salt was chemically stable (i.e., no disproportionationproduct observed in 48 hours) upon azeotropic drying in toluene atelevated temperature (up to 110° C.). Thus, drying of the reagentsuspension can be included as part of the process prior to the additionof OXOS and the preparation of SUL. By employing X-ray powderdiffraction analyses of oven-dehydrated samples, it was observed thatCALID underwent a polymorphic change upon complete drying (<100 ppmwater) at <15% RH. However, CALID is stable as a dehydrated material andconverts back to the original dihydrate form upon water re-adsorptionat >20% relative humidity. The process for manufacturing SUL includesthe drying of CALID and OXOS toluene suspensions by azeotropicdistillation under reduced pressure to prepare mixtures containing lessthan 100 ppm of water. The dry suspensions are then combined and asolvent exchange to dimethylacetamide is conducted (Scheme 13). Theresultant solution is heated to 120° C. and agitated for up to 20 hours.During this time, the sulfinate esters, generated within the first hourat 120° C., rearrange to form SUL. The typical levels of the ALCimpurity formed under these conditions are 3 LC area %. SUL is isolatedin 82% yield and >99.5 LC area % after an aqueous work-up andcrystallization from acetonitrile and water (up to 23.3 kg scale).

Isopropyl magnesium chloride was prepared in situ as a dry reagent andemployed directly in the manufacture of SUL, offering an alternativestrategy for the manufacture of SUL from OXOS. As shown in Scheme 14, atetrahydrofuran solution of isopropyl magnesium chloride was treatedwith sulfur dioxide to prepare isopropylsulfinate magnesium chloride.In-situ FTIR (with a peak at 1325 cm⁻¹) was used to verify completeconsumption of the sulfur dioxide. A phenanthroline test was employed toconfirm the absence of alkyl Grignard prior to subsequent processing.Solvent exchange to N-methylpyrrolidinone (NMP) was followed by theaddition of OXOS to afford SUL at 120° C. or 180° C. (Scheme 14).Elimination of undesired moisture and/or magnesium chloride hydroxidefrom the reaction mixture thus prepared is challenging. For instance,when three equivalents of isopropylsulfinate magnesium chloride areemployed relative to OXOS, approximately 5 mol % of magnesium chloridehydroxide (relative to OXOS) is present in the starting Grignardsolution. NMP (5 volumes) and OXOS incorporate 5-10 mol % of water(relative to OXOS). It is thus difficult to avoid the formation of aminimum of 15 mol % of ALC using this reagent. Interestingly, the levelsof ALC observed during the formation of SUL under these conditionsexceed the measured amount of water or hydroxide contained in thereaction mixture by a margin that depends on the operating temperature.A second mechanism, in addition to the direct opening of OXOS with wateror a hydroxide salt (Scheme 4), must be invoked to account for theformation of ALC. This postulated mechanism involves the reaction ofSULFI with isopropylsulfinate magnesium chloride to afford ALC (Scheme15).

There is an operative mechanism that explains the conversion of ALC toSUL at elevated temperatures (e.g., 180° C.), but it does not occur at acommercially suitable rate at 120° C. (FIG. 4 ). Treatment of OXOS withisopropylsulfinate magnesium chloride (3 equivalents) in NMP (5 volumes)at 180° C. allows the formation of SUL and ALC in 77% and 18% assayyields, respectively, after 6 minutes. After 80 minutes, the assayyields of SUL and ALC are 90% and 5%, respectively (FIG. 5 ). It isproposed that the magnesium salts act as Lewis acids, facilitating theformation of OXOS from ALC (Scheme 15). Isopropylsulfinate magnesiumchloride has poor stability at elevated temperatures and has beenobserved by ¹H NMR to experience 85% degradation over 1 hour at 200° C.as a 1 M solution in NMP. Consequently, three equivalents ofisopropylsulfinate magnesium chloride were utilized to carry out thetransformation.

Use of alternative isopropylsulfinate salts to modify the reactivity andto increase the stability of isopropylsulfinate magnesium chloride wasevaluated. Treatment of one equivalent of the in-situ prepared reagentwith one equivalent of zinc chloride afforded promising results. Acommercially available zinc chloride tetrahydrofuran solution (0.5 M)was added to the solution of isopropylsulfinate magnesium chlorideprepared as previously described (Scheme 12). The new species formed wasobserved to be distinct from isopropylsulfinate magnesium chloride andzinc isopropylsulfinate by ¹H NMR (FIG. 6 ) and its structure waspostulated to be that of isopropylsulfinate zinc chloride, withmagnesium chloride generated as a by-product. A solvent exchange to NMP(5 volumes) was performed and OXOS was added to the reaction mixture(Scheme 16). Using this mixed reagent, the conversion of ALC to SUL wasoperative at a productive rate at 120° C. Thus, the conversion can beperformed at 120° C. while avoiding decomposition of reagents andreaction intermediates (FIG. 7 ) and very rigorous moisture-freeconditions. Moreover, there is no evidence of an alternative mechanismaffording ALC without the involvement of water with this mixedmagnesium-zinc reagent, all the ALC generated during the process can beaccounted for from the incoming reagents or solvent. This is not to saythat this mixed salt cannot be used at 180° C. (FIG. 8 ), but atemperature of 140° C. was selected to carry out the process, allowing agood reaction rate while using limited equivalents (1.5 equivalents) ofthe magnesium-zinc species and affording a 90% yield of SUL with 7% ALCin 7 hours. The magnesium-zinc mixed species was shown to stable at 150°C. for 16 hrs by ¹H NMR experiments.

The robustness of this process was evaluated using a 20% excess ofsulfur dioxide during the formation of the isopropylsulfinate magnesiumchloride and performing the solvent exchange to NMP after 24 hrs ofagitation of the mixed salt at 20° C. It was observed that only 40% (by¹H NMR) of the sulfinate reagent remained and that 60% of the materialhad disproportionated to form sulfone SSO (Scheme 15). Using thismixture to convert OXOS to SUL with 1.5 equivalents of the reagentresulted in the formation of SUL in only 62 LC area % and left 33 LCarea % of OXOS unreacted, thus demonstrating a lack of robustness forthis process since it may prove problematic to control the sulfurdioxide dosing during plant operations. The use of CALID to prepare SULtherefore represents an advantageous aspect of the commercial process tomanufacture Compound A.

Example 5: Development of a Commercial Process to Prepare Compound A

Ozonolysis of the alkene group of SUL followed by oxidation of theresulting aldehyde to the corresponding carboxylic acid group ofCompound A with sodium chlorite presents a greener alternative to theruthenium oxide/sodium periodate method used for the initial manufactureof Compound A. In addition, the ozonolysis route would likely eliminatethe formation of several undesired dimeric impurities that are difficultto remove via crystallization and thus simplify isolation of theproduct.

In developing safe reaction conditions for the ozonolysis, an aqueousmixture was utilized (Scheme 17). Under these conditions, the highenergy ozonide intermediate (OZO) is hydrolyzed, thus avoiding itsaccumulation and making the process safe. The LC area % of accumulatedOZO was measured relative to the volumetric percentage of water used inthe acetonitrile/water reaction mixture with the results being reportedin FIG. 9 . With 10% water, the total energy release for the ozonolysismixture (20 volumes of solvent) is 92 J/g with a decompositiontemperature of 240° C., which does not represent a safety concern.Another parameter requiring control to ensure safety during theozonolysis is the gas phase concentration of oxygen in the vessel duringthe reaction.

The limiting oxygen concentration (LOC) for combustion of the mixturewas measured at 10.75 vol % and the ozonolysis process was conducted athalf the LOC (˜5 vol % oxygen) to ensure a comfortable margin of safetyto avoid possible combustion.

Two different modes of processing have been practiced in the GMP settingfor this transformation: (i) a semi-batch ozonolysis using ozonesparging in a batch vessel; and (ii) a continuous stirred-tank reactorprocess. At the outset, a continuous process appears attractive toalleviate the general safety concerns associated with employing anozonolysis reaction in a commercial process. A schematic and a pictureof the continuous ozonolysis apparatus utilized in one embodiment arepresented in FIGS. 10 and 11 , respectively. A CFS-3 ozone generatormodel marketed by Ozonia was utilized to process 4.8 kg of SUL whileproducing approximately 0.9 mol of ozone per hour. The ozone isgenerated from an air supply and introduced via a valve located at thebottom of a continuous stirred-tank reactor (CSTR), as shown in FIG. 10. The starting material solution is introduced at a flow rate of 60mL/minute using a dip tube with an outlet above the glass frit locatedat the bottom of the vessel (0.9 L capacity). Vigorous agitation of themixture is important for proper gas dispersion and an example can beseen in FIG. 11 . A nitrogen headspace purge having 3×the flow rate ofthe air flow introduced at bottom is maintained, thus ensuring that lessthan 5 vol % of oxygen/ozone is present in the gas phase. The reactionmixture is maintained at 20° C. using jacket control. A Raman probe isused at the CSTR outlet to measure the levels of residual SUL.

To minimize the risk in using continuous ozonolysis, accumulatedreaction mixture portions were sampled and reaction completion wasverified by HPLC. The portions were charged to a 2M aqueous solution ofsodium chlorite (4 equivalents) and the resultant mixture agitated for16 hours at 20° C. Due to the low solubility of the processintermediates (ALD, PAC) in aqueous solutions, addition of the aqueoussolution of sodium chlorite to the ozonolysis reaction stream ispreferable to the option used to avoid initial precipitation of thoseintermediates and represents the mode of addition used for thesemi-batch ozonolysis process described below.

A semi-batch approach for performing the ozonolysis of SUL has theadvantages of processing with an excess of the alkene starting materialfor most of the transformation and employing a simpler manufacturingfootprint. A maximum of 0.4 LC area % of impurity DHCA was observed tobe formed using this process mode but a dependable approach is requiredto monitor reaction completion and safe processing conditions. Asdescribed above, safe processing conditions for this reaction manifoldare provided by employing an aqueous medium and by maintaining theoxygen concentration below 5 vol %. The air/ozone gas stream is dilutedwith nitrogen downstream of the ozone generator but upstream of theintroduction of the reacting gas through a dip tube in the reactionvessel, as seen in FIG. 12 . A gas flow of nitrogen was used four timescompared to the air flow, ensuring that gas entering the vessel containsno more than 5 vol % of oxygen/ozone. A headspace ozone detector can beutilized to monitor reaction completion for ozonolysis by measuring anincrease in outlet gas concentration. However, this technique was foundto be difficult to implement considering that measured changes in theoutlet ozone concentration can be subtle. On the other hand, startingmaterial consumption has been found to be linear for this transformation(FIG. 13 ), thus enabling HPLC analysis of a few samples during thetransformation coupled with the knowledge of the ozone generator outputto accurately predict the time for reaction completion. A CFS-14 ozonegenerator model marketed by Ozonia, allowing a maximum output ofapproximately 540 g of ozone/hour was utilized to process a 23 kg batchof SUL. However, a stable ozone output is easier to maintain with theinstrument at less than maximum capacity, and thus an output of 285 g ofozone/hour was utilized for manufacturing and achieved 6080 W power (80%of capacity) and 3.1 SCFM (30% of maximum air flow). The concentrationof ozone in the generator output gas was approximately 4.3 wt % usingthese settings and this gas stream was mixed with nitrogen (12.5 SCFM)prior to entering the processing vessel. The predicted time to reactioncompletion using the ozone gas output (7.4 hours) was exceeded by 10%(8.2 hours actual). Ozone is known to react with water to generatehydroxy radical and a portion of the ozone is consumed in this manner,which explains the excess ozone that must be utilized.

For this semi-batch processing, ozone is introduced near the bottom ofthe reaction vessel via a dip tube. The first device evaluated todeliver gas to the reaction system was a standard ozone sparging unitwith 100 μm pore size and a 0.32 square feet total surface. Upon usingthis sparger to deliver 15.6 SCFM of combined gas flow (air, ozone, andnitrogen), a pressure drop occurred causing cooling of the spargersurface. This decrease in temperature was accompanied by crystallizationof the starting material SUL and product ALD, followed by obstruction ofthe sparger pores by the crystallized material. The solubility of SULand ALD at 10° C. in acetonitrile/water (9/1 volume ratio) is 25 mg/mLand 21 mg/mL, respectively, and thus only about 50% of either materialcan be solubilized at that temperature in 20 volumes of the solventmixture used. Once the sparger is obstructed by starting material orproduct crystals, the available surface for gas transfer decreases, andthe situation is exacerbated, requiring interruption of the process andrepair of the sparger. A different ozone sparger was engineering toaddress this problem. The alternative sparger incorporated ⅛-inchdiameter holes pierced in a C22 Hastelloy tube (37 holes). Both spargersare shown in FIG. 14 . The impact of using either spargers on reactionmixture and sparger surface temperatures at typical gas flow (15 SFCM)was measured and the results are shown in Table 3. As detailed in thetable, there was a significant difference (30° C. vs 11° C. for example)between the sparger surface and the reaction mixture temperatures forthe 100 μm pore sparger, causing the problems detailed above. Thealternative sparger alleviates these concerns. To avoid anyprecipitation of SUL and ALD during the ozonolysis process, thetransformation was conducted at 30° C.

TABLE 3 Sparger Surface Temperature Control using Different Spargers GasFlow Sparger Reaction mixture Sparger surface (SFCM) pore-size temp (°C.) temp (° C.) 15 100 12 2 15 100 30 11 15 ⅛-inch 13 11 15 ⅛-inch 25 22

After completion of the ozonolysis process, addition of the 2M aqueoussodium chlorite solution was observed to enable the formation ofCompound A. The mixture is treated with 2M aqueous sodium bisulfite toeliminate all oxidants for further processing. Phase separation wasfollowed by addition of isopropyl acetate, and two washings of theorganic layer with 2M aqueous sodium phosphate (pH 6) were conducted.Finally, the organic phase was washed with 1.1 M aqueous sodium chlorideto prepare a solution of Compound A in >95% assay yield and >98 LC area% purity.

Example 6: Isolation of Compound A as a DABCO Salt

Considering that a drug substance control point enabling a robustremoval of impurities was not available for the free-acid, several saltsof Compound A were prepared and tested to discover an effectivecandidate to allow for the facile removal of impurities. Over thirtyorganic salts and five inorganic salts of Compound A were evaluated forthat purpose, facilitating the identification of a hemi-DABCO salt and ahemi-calcium salt as promising contenders. However, the hemi-calciumsalt displayed only a moderate removal of the starting material SUL orthe impurity HAC whereas use of the hemi-DABCO isopropyl acetate salt(232-DAB) allowed for the efficient removal of both species(IPAC=isopropyl acetate).

Five (5) LC area % of SUL and 1 LC area % of HAC could be completelyremoved during the isolation of the latter salt, levels which aresignificantly higher than observed in a typical ozonolysis-Pinnickoxidation reaction mixture. 232-DAB has been observed to be a stablecrystalline mono-solvate (isopropyl acetate) hemi-DABCO salt by TGA and¹H NMR. A single polymorph of the material has been identified. Thepolymorphic form and the isopropyl acetate level of the material wasunchanged by a dynamic vapor sorption experiment conducted from 0 to 90%relative humidity. In addition, a robust crystallization protocol basedon temperature and the use of an anti-solvent could be designed for thehemi-DABCO isopropyl acetate salt using isopropyl acetate and heptane.

A solubility curve displaying values at different time intervals in thecrystallization process is shown in FIG. 15 . Upon the addition of DABCO(0.5 equivalents) to a solution of Compound A in four volumes ofisopropyl acetate at 55° C., the solution is seeded with 232-DAB,allowing supersaturation release and crystallization of approximately20% of the material. Cooling to 20° C. in 2 hours prompts another 60% ofthe material to crystallize. Four volumes of heptane are subsequentlyadded to lower the supernatant concentration to approximately 5 mg/mL inpreparation for batch filtration. Using this crystallization procedureallows for the isolation of 232-DAB in 83% yield and >99.9 LC area %purity (up to 23.2 kg scale).

Example 7: Isolation of Compound A

An aqueous crystallization protocol was desired to isolate Compound Avia an orthogonal purification process considering that thecrystallization 232-DAB was performed in organic solvents. Alcohol-watersolvent mixtures could not be utilized for the crystallizationconsidering the general instability of Compound A in alcohol solventsabove 20-30° C. due to Fischer esterification and the inability toremove the ester impurities via crystallization. Other aqueous mixtureswith water-miscible solvents showed steep solubility curves that werenot conducive to crystallization design. In contrast, acetic acid andwater was suitable to crystallize the material without the drawbacksdetailed above and with good growth characteristics. A robusttemperature and anti-solvent based crystallization was designed usingthis solvent mixture and operated after a salt break in an aqueoushydrochloric acid (2 equivalents)/isopropyl acetate mixture, twosubsequent washings of the organic layer with 2M aqueous sodiumphosphate (pH 6), a washing with 1.1 M aqueous sodium chloride, and asolvent exchange from isopropyl acetate to acetic acid.

A curve showing solubility values at different time points in thecrystallization process is represented in FIG. 16 . An acetic acidsolution (6.6 volumes of acetic acid) of Compound A is warmed to 55-60°C. and 4.4 volumes of water are added. The solution is seeded withCompound A, allowing supersaturation release and crystallization ofapproximately 30% of Compound A. The crystallization is cooled to 20° C.in 10 hours, resulting in the crystallization of another 55% of thematerial. One volume of water is subsequently added to lower thesupernatant concentration to approximately 5 mg/mL in preparation for arapid batch filtration. Three water washings (3×10 volumes) wereconducted to minimize the presence of residual acetic acid in theisolated material. Compound A (up to 18.0 kg) was isolated using thisprotocol in >92% isolated yield (100 wt %) and >99.9 LC area % puritywith <200 ppm of residual water and <200 ppm of residual acetic acid.

The material was milled using a Pallman Universal Mill (wing beater, upto 16 kg scale) and the results are summarized in Table 4. The targetd50 for Compound A was set at <35 μm based on oral absorption modeling(GastroPlus v 9.0) for the range of doses evaluated (60 to 480 mg) toprovide complete absorption at fasted gastric pH of 1.3.

TABLE 4 Compound A Particle Size Distribution Pre and Post Dry-MillingMaterial d10 (μm) d50 (μm) d90 (μm) Compound A 14.6 42.5 102 unmilledCompound A 3.2 19.1 43.7 milled

A robust and efficient process suitable for the commercial manufactureof a drug substance (Compound A) in high purity has been developed.Significant aspects of the process include: (i) the use of abench-stable Vilsmeier reagent, methoxymethylene-N,N-dimethyliminiummethyl sulfate, for selective in situ activation of a primary alcoholintermediate; (ii) the isolation of intermediate DHO in crystallineform, which enhances the capacity of the process capacity to removeimpurities; (iii) the use of a new and stable isopropyl calciumsulfinate reagent in crystalline form to ensure the robust preparationof a sulfone intermediate; (iv) the development of a safe ozonolysisprotocol conducted in an aqueous solvent mixture that is suitable foreither a batch or continuous manufacturing mode; (v) enhanced puritycontrol of Compound A by formation of a salt of Compound A that allowsfor effective removal of impurities. The new process was demonstrated toprovide 18 kg of pure Compound A (99.9 LC area %) in 49.8% overall yieldfrom DLAC, representing a significant improvement over the described FIHprocess which only resulted in a 32% overall yield.

What is claimed is:
 1. A process of preparing compound

the process comprising: reacting

with methoxymethylene-N,N-dimethyliminium methyl sulfate.
 2. The processof claim 1, wherein the reaction is carried out in the presence of abase.
 3. The process of claim 2, wherein the base is KOAc, NaOAc, LiOAc,or K₂CO₃.
 4. The process of claim 2, wherein the base is NaOAc.
 5. Theprocess of any one of claims 1-3, wherein the reaction is carried out ina solvent.
 6. The process of claim 5, wherein the solvent is toluene. 7.A process of preparing compound

the process comprising: reacting

with isopropylsulfinate zinc chloride.
 8. The process of claim 7,wherein the reaction is carried out in presence of a magnesium salt. 9.The process of claim 8, where the magnesium salt is MgCl₂.
 10. Theprocess of claim 7, wherein the isopropylsulfinate zinc chloride isgenerated in situ from isopropyl magnesium chloride.
 11. The process ofclaim 7, wherein the reaction is carried out at a range of 100° C. to150° C.
 12. The process of claim 7, wherein the reaction is carried outat a range of 150° C. to 200° C.
 13. A crystalline form of(1R,2R,4S)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-4-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)-4-methylhept-6-en-1-ol(DHO) characterized by a reflection X-ray powder diffraction patterncomprising peaks at 7.3°±0.2° 2θ, 14.5°±0.2° 2θ, 15.8°±0.2° 2θ,15.9°±0.2° 2θ, and 23.1°±0.2° 2θ.
 14. The crystalline form of claim 13,wherein the reflection X-ray powder diffraction pattern furthercomprises peaks at 8.5°±0.2°±2θ, 10.0°±0.2°±2θ, 11.0°±0.2°±2θ,13.4°±0.2° 2θ, 18.8°±0.2° 2θ, and 22.0°±0.2° 2θ.
 15. The crystallineform of claim 14, wherein the reflection X-ray powder diffractionpattern further comprises one or more peaks at 6.3°±0.2°±2θ,10.5°±0.2°±2θ, 11.5°±0.2° 2θ, 12.8°±0.2° 2θ, 14.8°±0.2° 2θ, 15.2°±0.2°2θ, 17.0°±0.2° 2θ, 17.5°±0.2° 2θ, 17.8°±0.2° 2θ, 18.4°±0.2° 2θ,19.0°±0.2° 2θ, 19.7°±0.2° 2θ, 19.9°±0.2° 2θ, 20.7°±0.2° 2θ, 21.2°±0.2°2θ, 21.3°±0.2° 2θ, 22.4°±0.2°±2θ, 23.6°±0.2°±2θ, 24.2°±0.2° 2θ,24.9°±0.2° 2θ, 25.7°±0.2° 2θ, 26.3°±0.2°±2θ, 27.0°±0.2°±2θ, 28.3°±0.2°2θ, 28.7°±0.2° 2θ, 29.3°±0.2° 2θ, 29.7°±0.2°±2θ, 30.8°±0.2°±2θ,31.4°±0.2° 2θ, 31.8°±0.2° 2θ, 33.0°±0.2° 2θ, 34.2°±0.2° 2θ, 35.8°±0.2°2θ, 37.0°±0.2° 2θ, and 37.5°±0.2° 2θ.
 16. The crystalline form of claim13, wherein the crystalline form is a crystalline anhydrate.
 17. Thecrystalline form of any one of claims 13-16, wherein the peaks arepresent when the reflection x-ray powder diffraction is carried outusing Cu-Kα radiation.